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MICRO-RNAS OF THE MIR-15 FAMILY
MODULATE CARDIOMYOCYTE SURVIVAL
AND CARDIAC REPAIR
CROSS-REFERENCE TO RELATED
APPLICATIONS
This application is a continuation of U.S. application Ser.
No. 12/742,233, filedAug. 24, 2010, now U.S. Pat. No. 8,513,
209, which is a national stage application of International
Application No. PCT/US2008/083020,filed Nov. 10, 2008,
which claimsthe benefit ofU.S. Provisional Application No.
60/986,798,filed Nov. 9, 2007, each ofwhich is herein incor-
porated by reference in its entirety.
STATEMENT OF GOVERNMENT SUPPORT
This invention was made with grant support undergrantno.
HL53351-06 from the NationalInstitutes ofHealth. The gov-
ernmenthas certain rights in the invention.
DESCRIPTION OF THE TEXT FILE SUBMITTED
ELECTRONICALLY
The contents of the text file submitted electronically here-
with are incorporated herein by reference in their entirety: A
computer readable format copy ofthe Sequence Listing(file-
name: MIRG_002__02US_SeqList_ST25 txt, date
recorded: Aug. 19, 2013, file size 4 kilobytes).
FIELD OF THE INVENTION
The present invention relates generally to the fields of
developmental biology and molecular biology. More particu-
larly, it concerns gene regulation and cellular physiology in
cardiomyocytes. Specifically, the inventionrelates to a family
of miRNAs, designated as the miR-15 family, that regulate
cardiomyocyte survival and cardiac repair. Inhibition ofthese
miRNAsprovides for reduced apoptosis in cardiac cells and
thus inhibits cardiac hypertrophy andheart failure.
BACKGROUND OF THE INVENTION
Heart disease and its manifestations, including coronary
artery disease, myocardial infarction, congestive heart failure
and cardiac hypertrophy, clearly present a major health risk in
the United States today. The cost to diagnose, treat and sup-
port patients suffering from these diseases is well into the
billions of dollars. Two particularly severe manifestations of
heart disease are myocardial infarction and cardiac hypertro-
phy. With respect to myocardial infarction, typically an acute
thrombocytic coronary occlusion occurs in a coronary artery
as a result of atherosclerosis and causes myocardial cell
death. Because cardiomyocytes, the heart muscle cells, are
terminally differentiated and generally incapableofcell divi-
sion, they are generally replaced by scar tissue when they die
during the course of an acute myocardial infarction. Scar
tissue is not contractile, fails to contribute to cardiac function,
and often plays a detrimentalrole in heart functionby expand-
ing during cardiac contraction, or by increasing the size and
effective radius of the ventricle, for example, becoming
hypertrophic.
With respect to cardiac hypertrophy, one theory regards
this as a disease that resembles aberrant developmentand,as
such,raises the question ofwhether developmental signals in
the heart can contribute to hypertrophic disease. Cardiac
hypertrophy is an adaptive response ofthe heart to virtually
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all forms of cardiac disease, including those arising from
hypertension, mechanical load, myocardial infarction, car-
diac arrhythmias, endocrine disorders, and genetic mutations
in cardiac contractile protein genes. While the hypertrophic
response is initially a compensatory mechanism that aug-
ments cardiac output, sustained hypertrophy can lead to
dilated cardiomyopathy (DCM), heart failure, and sudden
death. In the United States, approximately half a million
individuals are diagnosed with heart failure each year, with a
mortality rate approaching 50%. The causes andeffects of
cardiac hypertrophy have been extensively documented, but
the underlying molecular mechanisms have not been eluci-
dated. Understanding these mechanismsis a major concern in
the prevention and treatment of cardiac disease and will be
crucialas a therapeutic modality in designing new drugsthat
specifically target cardiac hypertrophy andcardiac heart fail-
ure.
Treatment with pharmacological agents still represents the
primary mechanism for reducing or eliminating the manifes-
tations of heart failure. Diuretics constitute the first line of
treatment for mild-to-moderate heart failure. If diuretics are
ineffective, vasodilatory agents, such as angiotensin convert-
ing enzyme (ACE) inhibitors(e.g., enalopril and lisinopril) or
inotropic agent therapy (i.e., a drug that improves cardiac
output by increasing the force ofmyocardial muscle contrac-
tion) may be used. Unfortunately, many of these standard
therapies have numerous adverse effects and are contraindi-
cated in some patients. Thus, the currently used pharmaco-
logical agents have severe shortcomingsin particular patient
populations. The availability ofnew,safe and effective agents
would undoubtedly benefit patients who either cannot use the
pharmacological modalities presently available, or who do
not receive adequate relief from those modalities.
The adult heart is a dynamic organ capable of significant
remodeling and hypertrophic growth as a meansof adapting
function to altered workloads or injury. Hemodynamicstress
or neuroendocrine signaling associated with myocardial inf-
arction, hypertension, aortic stenosis, and valvular dysfunc-
tion evoke a pathologic remodeling response through the
activation of intracellular signaling pathways and transcrip-
tional mediators in cardiac myocytes. Activation of these
molecular pathways enhances cardiomyocyte size and pro-
tein synthesis, induces the assembly of sarcomeres, and
causes reexpression of fetal cardiac genes. Although aspects
of the hypertrophic response after acute and chronic stress
mayinitially augmentcardiac output, prolonged hypertrophy
is a major predictor of heart failure and sudden death. There
have been major advancesin the identification of genes and
signaling pathways involvedin this disease process, but the
overall complexity of hypertrophic remodeling suggests that
additional regulatory mechanisms remain to be identified.
MicroRNAs (miRNAsor miRs) have recently been impli-
cated in a numberofbiological processes including regula-
tion of developmental timing, apoptosis, fat metabolism, and
hematopoietic cell differentiation among others. MiRNAsare
small, non-protein coding RNAs of about 18 to about 25
nucleotides in length that regulate gene expression in a
sequence-specific manner. MiRNAsact as repressors oftar-
get mRNAs by promoting their degradation, when their
sequences are perfectly complementary, or by inhibiting
translation, when their sequences contain mismatches.
MiRNAsare transcribed by RNA polymeraseII (pol II) or
RNA polymeraseIII (polIIT; see Qi et al. (2006) Cellular &
Molecular ImmunologyVol. 3:411-419) andarise from initial
transcripts, termed primary miRNA transcripts (pri-miR-
NAs), that are generally several thousand bases long and are
derived from individual miRNA genes, from introns of pro-
US 9,078,919 B2
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tein coding genes, or from poly-cistronictranscripts that often
encode multiple, closely related miRNAs.See review of Car-
rington et al. (2003). Pri-miRNAs are processed in the
nucleus by the RNase Drosha into about 70- to about 100-
nucleotide hairpin-shaped precursors (pre-miRNAs). Fol-
lowing transport to the cytoplasm,the hairpin pre-miRNA is
further processed by Dicer to produce a double-stranded
miRNA (Leeet al., 1993). The mature miRNA strandis then
incorporated into the RNA-induced silencing complex
(RISC), where it associates with its target mRNAs by base-
pair complementarity. In the relatively rare cases in which a
miRNA base pairs perfectly with an mRNAtarget, it pro-
motes mRNA degradation. More commonly, miRNAs form
imperfect heteroduplexes with target mRNAs, affecting
either mRNAstability or inhibiting mRNAtranslation.
The 5' portion of a miRNAspanning bases 2-8, termed the
‘seed’ region, is especially important for target recognition
(Krenz and Robbins, 2004; Kiriazis and Kranias, 2000). The
sequence of the seed, together with phylogenetic conserva-
tion of the target sequence, forms the basis for many current
target prediction models. Although increasingly sophisti-
cated computational approachesto predict miRNAsandtheir
targets are becoming available, target prediction remains a
major challenge and requires experimental validation.
Ascribing the functions of miRNAsto the regulation of spe-
cific mRNA targets is further complicated by the ability of
individual miRNAsto base pair with hundreds of potential
high and low affinity mRNA targets and by the targeting of
multiple miRNAsto individual mRNAs.
The high sequence conservation of many miRNAsacross
metazoan species suggests strong evolutionary pressure and
participation in essential biologic processes (Reinhart et al.,
2000; Stark et al., 2005). Indeed, miRNAs have been shown
to play fundamentalroles in diverse biological and pathologi-
cal processes, including cell proliferation, differentiation,
apoptosis, and carcinogenesis in species ranging from Cae-
norhabditis elegans and Drosophila melanogaster to
humans. However, there remains limited information on the
role that miRNAsplay in cardiogenesis and molecular events
that can contribute to heart disease.
SUMMARYOF THE INVENTION
Thepresent invention provides a method oftreating patho-
logic cardiac hypertrophy, heart failure, or myocardial infare-
tion in a subject in need thereof. In one embodiment, the
method comprises identifying a subject having cardiac hyper-
trophy, heart failure, or myocardial infarction; and inhibiting
expression or activity of one or more milk-15 family mem-
bersin heart cells of said subject. In another embodiment, the
method further comprises administering to the subject a sec-
ond therapy. The second therapy maybe, for example, a beta
blocker, an ionotrope, a diuretic, ACE inhibitor, All antago-
nist, BNP, a Ca++-blocker, and ERA, or an Hum inhibitor.
In some embodiments of the invention, inhibiting the
expression oractivity ofone or more miR-15 family members
comprises administering an antagomir ofone ormore miR-15
family members. In one embodiment, the expressionor activ-
ity of one or more miR-15 family members is inhibited by
administering an antisense oligonucleotide that targets the
mature sequence of a milk-15 family member. In yet another
embodiment, expression or activity of one or more miR-15
family members is inhibited by administering an inhibitory
RNA molecule, wherein the inhibitory RNA molecule com-
prises a double stranded region that is at least partially iden-
tical and complementary to a mature sequence of a miR-15
family member. The inhibitory RNA molecule may be a
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ribozyme, siRNA or shRNA molecule. In still another
embodiment, expression or activity of one or more miR-15
family membersis inhibited by administering a nucleic acid
comprising one or more miR-15 binding sites. A miR-15
binding site may comprise a sequencethat is complementary
to aseed sequence ofmiR-15. The one ormore miR-15 family
members may be miR-15a, miR-15b, miR-16-1, miR-16-2,
miR-195, miR-424 and miR-497.
The present invention also provides a methodofpreventing
pathologic hypertrophy or heart failure in a subject in need
thereof. In one embodiment, the method comprises identify-
ing a subject at risk of developing pathologic cardiac hyper-
trophyor heart failure; and inhibiting expression or activity of
one or more miR-15 family membersin heart cells of said
subject. In one embodiment, inhibiting comprises delivering
to the heart cells an inhibitor of one or more miR-15 family
members. In another embodiment, the subject at risk may
exhibit one or more risk factors selected from the group
consisting of uncontrolled hypertension, uncorrected valvu-
lar disease, chronic angina, recent myocardial infarction, con-
genital predisposition to heart disease, and pathological
hypertrophy.
Antagomirs, antisense oligonucleotides, inhibitory RNA
molecules, nucleic acids comprising miR-15 binding sites or
other modulators of the expressionor activity of one or more
miR-15 family members may be administered by any method
knownto those in the art suitable for delivery to the targeted
organ, tissue, or cell type. For example, in certain embodi-
mentsofthe invention, the modulator ofone or more miR-15
family members may be administered by parenteral admin-
istration, such as intravenousinjection,intraarterial injection,
intrapericardial injection, or subcutaneous injection, or by
direct injection into the tissue (e.g., cardiac tissue). In some
embodiments, the modulator of one or more miR-15 family
members may be administered by oral, transdermal, intrap-
eritoneal, subcutaneous, sustained release, controlled release,
delayed release, suppository, or sublingual routes of admin-
istration. In other embodiments, the modulator ofone ormore
miR-15 family members may be administered by a catheter
system.
Thepresent invention also encompassesa transgenic, non-
human mammal, the cells ofwhichfail to express a functional
form of one or more miR-15 family members(e.g. miR-15a,
miR-15b, miR-16-1, miR-16-2, miR-195, miR-424 and miR-
497). In another embodiment, the present invention includes
a transgenic, non-human mammal, the cells of which com-
prise a coding region of a miR-15 family member under the
control of a heterologous promoter active in the cells of said
non-human mammal. In some embodiments, the mammalis
a mouse.
The present invention provides a methodfor identifying a
modulator of a miR-15 family member comprising (a) con-
tacting a cell with a candidate compound; (b) assessing activ-
ity or expression of an miR-15 family member; and (c) com-
paring the activity or expressionin step (b) with the activity or
expression in the absence of the candidate compound,
wherein a difference between the measured activities or
expression indicates that the candidate compoundis a modu-
lator of said miR-15 family member. The cell may be con-
tacted with the candidate compoundin vitro or in vivo. The
candidate compound maybea protein, a peptide, a polypep-
tide, a polynucleotide, an oligonucleotide, or small molecule.
The modulator ofa miR-15 family membermay be an agonist
or inhibitor of the miR-15 family member. The modulator of
amiR-15 family member maybe an agonistor inhibitor of an
upstream regulator of the miR-1.5 family member.
US 9,078,919 B2
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The present invention also provides a pharmaceutical com-
position comprising an inhibitor ofone or more miR-15 fam-
ily members. In one embodiment, the composition is formu-
lated for injection. In another embodiment, the
pharmaceutical composition is combined with a kit for
administration, such as parenteral or catheter administration.
BRIEF DESCRIPTION OF THE DRAWINGS
The following drawings form part of the present specifica-
tion and are includedto further demonstrate certain aspects of
the present invention. The invention maybebetterunderstood
by reference to one or more ofthese drawings in combination
with the detailed description of specific embodiments pre-
sented herein.
FIG. 1. MiRNA expression during cardiac hypertrophy. A.
H&Estained sections of representative hearts from mice fol-
lowing sham andthoracic aortic banding (TAB)for 21 days
and from wild-type (WT) and activated calcineurin trans-
genic (CnA Tg) mice. Scale bar equals 2 mm. B. Numbers of
miRNAsthat were regulated in response to CnA or TABare
indicated. Although some changes were unique for either
TAB or CnA-induced hypertrophy, most miRNAsthat were
induced or repressed overlapped for the different hyper-
trophic stimuli. C. Northern blot analysis of particular miR-
NAs in WT and CnA Tg hearts. U6 RNA wasdetected as a
loading control.
FIG. 2. MiRNA expression in humanheart failure. North-
ern blot analysis ofmiRNAsin 4 normaland6 failing human
hearts. The average fold-change ofeach miRNAinthe failing
samples is shownatthe right.
FIG. 3. Cardiac specific over-expression ofmiRNA 195 is
sufficient to drive cardiomyopathy. H&E stained sections of
hearts from wild-type (WT) and twodifferent lines of miR-
195 transgenic (Tg) animals. MiRNA-195 Tgline 3 animals
died two weeks after birth due to cardiac dilation. Northern
blot analysis on hearts from WTandmiR-195 transgenic lines
1 and 3 confirming a 26.5-fold and 29.2-fold cardiac specific
miRNAoverexpression, respectively.
FIG. 4. Overexpression of milt-195 induces cardiac dys-
function due to cardiac growth. A. Echocardiographic analy-
ses indicate miR-195 transgenic (Tg) mice showleft ventricu-
lar (LV) dilation and wall thinning, resulting in a decreased
fractional shortening compared to wild-type (WT)litter-
mates. B. Heart weight to body weight ratio increases in
response to cardiac specific overexpression of milk-195. C.
Realtime PCR analysis shows an upregulation of hyper-
trophic genes in miR-195 Tg animals compared to WT ani-
mals (n=3). *P<0.05 compared to wild-type.
FIG. 5. Cardiac remodeling specific for miR-195. Over-
expression ofmiR-195 induces cardiac growth at 2 weeks of
age, which within 6 weeksprogressesto a dilated phenotype.
Cardiac over-expression of miR-214 has no phenotypic
effect, indicating the specific effect of miR-195 on cardiac
pathology. Scale bar equals 2 mm.
FIG. 6. MiR-195is part of the miR-15 family that targets
pro-survival proteins. A. MiR-195 is part ofthe milk-15 fam-
ily that consists of five different miRs: miR-15, miR-16,
miR-195, miR-424, and miR-497. Four ofthe miR-15 family
membersare expressed as three dusters of two miRNAs. B.
MiR-15 family members target proteins involved in prolif-
eration, survival and anti-apoptosis. Thus, up-regulation of
miR-195 results in down-regulation ofthese mRNAsandcell
death.
FIG. 7. MiR-195 target sequence in the 3' UTR of FGF2
mRNA.
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FIG. 8. Enhanced expression ofmiR-15 family membersin
samples from failing human hearts. A. Left panel shows RNA
blots from normal humanhearts and right panel shows RNA
blots from failing human hearts. B. The conserved seed
region among milk-15 family members allows for an addi-
tional approach to knockdownthe whole miR-15 family. This
approach entails overexpression of multiple miR-15 binding
sites underthe control of a cardiac specific promoter, such as
the alpha myosin heavy chain promoter (@MHC). Each ofthe
miR-15 binding sites contains a sequence complementary to
the sequenceofthe conserved seed region and allows for the
scavenging of all family members, thereby preventing them
from binding to their endogenoustargets.
DETAILED DESCRIPTION OF ILLUSTRATIVE
EMBODIMENTS
The present invention is based, in part, on the discovery
that members of the miR-15 family of microRNAs, such as
miR-195, are upregulated in myocardial tissue from human
failing hearts as well as in animal models of pathologic car-
diac hypertrophy. Cardiac overexpression ofmiR-195 is suf-
ficient to induce cardiac hypertrophy andcanleadto a dilated
phenotype. Accordingly, the present invention provides
methods of treating or preventing various forms of heart
disease in a subject by inhibiting the expression oractivity of
one or more members of the miR-15 family in heart cells of
the subject.
The miR-15 family is a small family of microRNAsthat
includes miR-195, miR-16-1, miR-15a, miR-15b, miR-16-2,
miR-424, and miR-497. Four of the miR-15 family members
are expressedas three clustered transcripts (FIG. 6A). MiR-
195 and miR-497 are expressedas a duster from the intron of
a gene located on chromosome 17. There are two copies of
miR-16 located on different chromosomes. One copy (miR-
16-1)is expressed as a cluster with miR-15a from an intron of
a gene encoded on chromosome 13. The second copy (miR-
16-2) is expressed as a cluster with 15b from the intron ofthe
SMC4gene located on chromosome 3. MiR-424is expressed
from the X chromosome. The pre-miRNA sequences(e.g.
stem loop sequences) for each ofthe miR-15 family members
are listed below:
Human pre-miR-195
(SEQ ID NO:
UUGGCACAGG
1)
AGCUUCCCUG GCUCUAGCAG CACAGAAAUA
GAAGCGAGUC UGCCAAUAUU GGCUGUGCUG CUCCAGGCAG
GGUGGUG
Human pre-miR-497
(SEQ ID NO:
ACACUGUGGU
2)
CCACCCCGGU CCUGCUCCCG CCCCAGCAGC
UUGUACGGCA CUGUGGCCAC GUCCAAACCA CACUGUGGUG
UUAGAGCGAG GGUGGGGGAG GCACCGCCGA GG
Human pre-miR-16-1
(SEQ ID NO:
UGGCGUUAAG
3)
GUCAGCAGUG CCUUAGCAGC ACGUAAAUAU
AUUCUAAAAU UAUCUCCAGU AUUAACUGUG CUGCUGAAGU
AAGGUUGAC
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-continued
Human pre-miR-16-2
(SEQ ID No:
GUAGUGAAAUGUUCCACUCU AGCAGCACGU AAAUAUUGGC
AUAUAUUAAA CACCAAUAUU ACUGUGCUGC UUUAGUGUGA
Human pre-miR-15a
(SEQ ID No:
UUGUGGAUUUCCUUGGAGUA AAGUAGCAGC ACAUAAUGGU
UGAAAAGGUG CAGGCCAUAU UGUGCUGCCU CAAAAAUACA AGG
Human pre-miR-15b
(SEQ ID No:
CAUGGUUUACUUGAGGCCUU AAAGUACUGU AGCAGCACAU
AUGCUACAGU CAAGAUGCGA AUCAUUAUUU GCUGCUCUAG
AAAUUUAAGG AAAUUCAU
Human pre-miR-424
(SEQ ID NO:
AAGUGUUCUA
19)
CGAGGGGAUA CAGCAGCAAU UCAUGUUUUG
AAUGGUUCAA AACGUGAGGC GCUGCUAUAC CCCCUCGUGG
GGAAGGUAGA AGGUGGGG
Eachofthe pre-miRNA sequences for each miR-15 family
member is processed into a mature sequence and astar
sequence. The star sequence is processed from the other
strand of the stem loop structure. The mature and star
sequences for each of the miR-15 family membersis given
below:
Human mature miR-195
(SEQ ID NO: 7)
UAGCAGCACAGAAAUAUUGGC
Human miR-195*
(SEQ ID NO: 8)
CCAAUAUUGGCUGUGCUGCUCC
Human mature miR-497
(SEQ ID NO: 9)
CAGCAGCACACUGUGGUUGU
Human miR-497*
(SEQ ID NO: 10)
CAAACCACACUGUGGUGUUAGA
Human mature miR-16-1/miR-16-2
(SEQ ID NO: 11)
UAGCAGCACGUAAAUAUUGGCG
Human miR-16-1*
(SEQ ID NO: 12)
CCAGUAUUAACUGUGCUGCUGA
Human miR-16-2*
(SEQ ID NO: 13)
CCAAUAUUACUGUGCUGCUUA
Human mature miR-15a
(SEQ ID NO: 14)
UAGCAGCACAUAAUGGUUUGUG
Human miR-15a*
(SEQ ID NO: 15)
CAGGCCAUAUUGUGCUGCCUCA
Human mature miR-15b
(SEQ ID NO: 16)
UAGCAGCACAUCAUGGUUUACA
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-continued
Human miR-15b*
(SEQ ID NO: 17)
CGAAUCAUUAUUUGCUGCUCUA
Human mature miR-424
(SEQ ID NO: 20)
CAGCAGCAAUUCAUGUUUUGAA
Human miR-424*
(SEQ ID NO: 21)
CAAAACGUGAGGCGCUGCUAU
Althoughthe seed region (e.g. bases spanning 2 to 8 nucle-
otides ofmature miRNA sequence)for all family membersis
highly conserved (AGCAGCAC; SEQ ID NO:18), the 3' end
of the mature miRNA differs among the different family
members(FIG. 6A).
The present invention provides a methodoftreating patho-
logic cardiac hypertrophy, heart failure, or myocardialinfare-
tion in a subject in need thereof by inhibiting expression or
activity of one or more miR-15 family members. In one
embodiment, the method comprises identifying a subject hav-
ing cardiac hypertrophy, heart failure, or myocardial infarc-
tion; and inhibiting expression or activity of one or more
milk-15 family members in heart cells of said subject. “Heart
cells” as used herein include cardiomyocytes, cardiac fibro-
blasts, and cardiac endothelial cells. In another embodiment,
the method comprises administering to the subject an inhibi-
tor of one or more miR-15 family members. Instill another
embodiment, the method comprises identifying a subject at
risk of developing pathologic cardiac hypertrophy or heart
failure and inhibiting expression or activity of one or more
miR-15 family members in heart cells of the subject. The
subject at risk of developing pathologic cardiac hypertrophy
or heart failure may exhibit one or moreriskfactors including,
for example, uncontrolled hypertension, uncorrected valvular
disease, chronic angina, recent myocardial infarction, con-
genital predispositionto heart disease or pathological hyper-
trophy. In certain embodiments, the subject at risk may be
diagnosed as having a genetic predisposition to cardiac
hypertrophy. In some embodimentsofthe invention, the sub-
ject at risk may have a familialhistory ofcardiac hypertrophy.
In another embodiment, the present invention provides a
methodofpreventing cardiac hypertrophy anddilated cardi-
omyopathy in a subject in need thereof comprising inhibiting
expression oractivity ofone ormore miR-15 family members
in heart cells of the subject. In yet a further embodiment, the
present invention provides a methodofinhibiting progression
ofcardiac hypertrophy ina subject in need thereofcomprising
inhibiting expression or activity ofone or more milk-15 fam-
ily membersin heart cells of the subject. In further embodi-
ments, the present invention provides a method of increasing
exercise tolerance, reducing hospitalization, improving qual-
ity oflife, decreasing morbidity, and/or decreasing mortality
in a subject with heart failure or cardiac hypertrophy com-
prising inhibiting expression oractivity of one or more milk-
115 family membersin heart cells of the subject.
Thus, the present invention provides methodsfor the treat-
ment of cardiac hypertrophy, heart failure, or myocardial
infarction utilizing inhibitors of miR-15 members, such as
miR-195, miR-15a, miR-15b, miR-16-1, miR-424, and miR-
497. Preferably, administration of an inhibitor of a miR-15
family memberresults in the improvement of one or more
symptomsof cardiac hypertrophy, heart failure, or myocar-
dial infarction in the subject, or in the delay in the transition
from cardiac hypertrophy to heart failure. The one or more
improved symptoms maybe, for example, increased exercise
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9
capacity, increased cardiac ejection volume, decreased left
ventricular end diastolic pressure, decreased pulmonary cap-
illary wedge pressure, increased cardiac output, increased
cardiac index, lowered pulmonary artery pressures,
decreased left ventricular end systolic and diastolic dimen-
sions, decreased left and right ventricular wall stress,
decreased wall tension, increased quality of life, and
decreased disease related morbidity or mortality. In addition,
use of inhibitors of milk-15 family members may prevent
cardiac hypertrophy and its associated symptoms from aris-
ing. In one embodiment, administration ofan inhibitor ofone
or more miR-15 family members to a subject suffering from
myocardial infarction may reduce infarct size by decreasing
the loss of heart cells. In another embodiment, cardiac func-
tion is stabilized in a subject suffering from myocardial inf-
arction following administration of an inhibitor of one or
more miR-15 family members.
Inhibition of microRNA function may be achieved by
administering antisense oligonucleotides targeting a mature
sequence of a miR-15 family member. The antisense oligo-
nucleotides may be ribonucleotides or deoxyribonucleotides.
Preferably, the antisense oligonucleotides have at least one
chemical modification. Antisense oligonucleotides may be
comprised of one or more “locked nucleic acids”, “Locked
nucleic acids” (LNAs) are modified ribonucleotides that con-
tain an extra bridge betweenthe 2' and 4' carbonsofthe ribose
sugar moiety resulting in a “locked” conformation that con-
fers enhanced thermalstability to oligonucleotides contain-
ing the LNAs. Alternatively, the antisense oligonucleotides
may comprise peptide nucleic acids (PNAs), which contain a
peptide-based backbonerather than a sugar-phosphate back-
bone. Other chemical modifications that the antisense oligo-
nucleotides may contain include, but are not limited to, sugar
modifications, such as 2'-O-alkyl (e.g. 2'-O-methyl, 2'-O-
methoxyethyl), 2'-fluoro, and 4' thio modifications, and back-
bone modifications, such as one or more phosphorothioate,
morpholino, or phosphonocarboxylate linkages (see, for
example, U.S. Pat. Nos. 6,693,187 and 7,067,641, which are
herein incorporated by reference in their entireties). In some
embodiments, suitable antisense oligonucleotides are 2'-O-
methoxyethyl “gapmers” which contain 2'-O-methoxyethyl-
modified ribonucleotides on both 5' and 3' ends with at least
ten deoxyribonucleotides in the center. These “gapmers”are
capable of triggering RNase H-dependent degradation
mechanisms of RNA targets. Other modifications of anti-
sense oligonucleotides to enhancestability and improveeffi-
cacy, such as those described in U.S. Pat. No. 6,838,283,
whichis herein incorporated by reference in its entirety, are
knownintheart andare suitable for use in the methods ofthe
invention. Preferable antisense oligonucleotides useful for
inhibiting the activity ofmicroRNAsare about 19 to about 25
nucleotides in length. Antisense oligonucleotides may com-
prise a sequencethatis at least partially complementary to a
mature miRNA sequence,e.g. at least about 75%, 80%, 85%,
90%, 95%, 96%, 97%, 98%, or 99% complementary to a
mature miRNA sequence. In some embodiments, the anti-
sense oligonucleotide may be substantially complementary
to amature miRNAsequence,thatis at least about 95%, 96%,
97%, 98%, or 99% complementary to a target polynucleotide
sequence. In one embodiment, the antisense oligonucleotide
comprises a sequence that is 100% complementary to a
mature miRNA sequence.
In some embodiments, the antisense oligonucleotides are
antagomirs. “Antagomirs” are single-stranded, chemically-
modified ribonucleotides that are at least partially comple-
mentary to the miRNA sequence. Antagomirs may comprise
one or more modified nucleotides, such as 2'-O-methy]-sugar
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modifications. In some embodiments, antagomirs comprise
only modified nucleotides. Antagomirs may also comprise
one or more phosphorothioate linkages resulting in a partial
or full phosphorothioate backbone.To facilitate in vivo deliv-
ery andstability, the antagomir maybe linked to a cholesterol
or other moiety at its 3" end. Antagomirs suitable for inhibit-
ing miRNAs may be about 15 to about 50 nucleotides in
length, more preferably about 18 to about 30 nucleotides in
length, and most preferably about 20 to about 25 nucleotides
in length,“Partially complementary”refers to a sequencethat
is at least about 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%,
or 99% complementary to a target polynucleotide sequence.
The antagomirs maybeat least about 75%, 80%, 85%, 90%,
95%, 96%, 97%, 98%, or 99% complementary to a mature
miRNAsequence.In some embodiments, the antagomir may
be substantially complementary to a mature miRNA
sequence, that is at least about 95%, 96%, 97%, 98%, or 99%
complementary to a target polynucleotide sequence. In other
embodiments, the antagomirs are 100% complementary to
the mature miRNA sequence.
Another approach for inhibiting the function of a miR-15
family memberis administering an inhibitory RNA molecule
having a double strandedregionthatis at least partially iden-
tical and partially complementary to a mature sequenceofthe
miR-15 family member. The inhibitory RNA molecule may
be a double-stranded, small interfering RNA (siRNA)or a
short hairpin RNA molecule (shRNA) comprising a stem-
loop structure. The double-stranded regions ofthe inhibitory
RNA molecule may comprise a sequence that is at least
partially identical and partially complementary, e.g. about
75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% iden-
tical and complementary, to the mature miRNA sequence. In
some embodiments, the double-stranded regions of the
inhibitory RNA comprise a sequencethat is at least substan-
tially identical and substantially complementary to the
mature miRNA sequence. “Substantially identical and sub-
stantially complementary”refers to a sequencethatis at least
about 95%, 96%, 97%, 98%, or 99% identical and comple-
mentary to a target polynucleotide sequence. In other
embodiments, the double-stranded regions of the inhibitory
RNA molecule may contain 100% identity and complemen-
tarity to the target miRNA sequence.
The inhibitory nucleotide molecules described hereinpref-
erably target a mature sequence ofone ormore miR-15 family
members(e.g. SEQ ID NOs:7, 9, 11, 14, 16, and 20) or a star
sequence of one or more miR-15 family members (e.g. SEQ
ID NOs:8, 10, 12, 13, 15, 17, and 21). Insome embodiments,
inhibitors of miR-15 family members are antagomirs com-
prising a sequence that is perfectly complementary to a
mature sequence ofa miR-15 family member. In one embodi-
ment, an inhibitor of a miR-15 family memberis an antago-
mir having a sequencethat is partially or perfectly comple-
mentary to SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11,
SEQ ID NO: 14, SEQ ID NO: 16, or SEQ ID NO:20. In
another embodiment, an inhibitor of a miR-15 family mem-
ber is an antagomir having a sequence that is partially or
perfectly complementary to SEQ ID NO: 8, SEQ ID NO:10,
SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID
NO: 17, or SEQ ID NO:21.
In some embodiments, inhibitors of one or more miR-15
family members are chemically-modified antisense oligo-
nucleotides, in one embodiment, an inhibitor of a miR-15
family member is a chemically-modified antisense oligo-
nucleotide comprising a sequence substantially complemen-
tary to SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO: 11, SEQ
ID NO: 14, SEQ ID NO: 16, or SEQ ID NO:20. In another
embodiment, an inhibitor of a miR-15 family memberis a
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chemically-modified antisense oligonucleotide comprising a
sequence substantially complementary to SEQ ID NO:8,
SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID
NO: 15, SEQ ID NO: 17, or SEQ ID NO:21. As used herein
“substantially complementary”refers to a sequencethatis at
least about 95%, 96%, 97%, 98%, 99%, or 100% comple-
mentary to a target polynucleotide sequence (e.g. mature or
precursor miRNA sequence).
Antisense oligonucleotides may comprise a sequence that
is substantially complementary to a precursor miRNA
sequence(pre-miRNA)for one or more miR-15 family mem-
bers (e.g. pre-miR-195, pre-miR-497, pre-miR-424, pre-
miR-15a, pre-miR-15b, pre-miR-16-1, or pre-miR-16-2). In
some embodiments, the antisense oligonucleotide comprises
a sequencethat is substantially complementary to a sequence
located outside the stem-loop region of the pre-miRNA
sequence. In one embodiment, an inhibitor of a miR-15 fam-
ily memberis an antisense oligonucleotide having a sequence
that is substantially complementary to a pre-miRNA
sequenceselected from the group consisting of SEQ ID NO:
1, SEQ ID NO:2, SEQID NO: 3, SEQID NO: 4, SEQID NO:
5, SEQ ID NO:6, and SEQ ID NO:19.
In other embodiments ofthe invention, inhibitors ofone or
more miR-15 family members may be inhibitory RNA mol-
ecules, such as ribozymes, siRNAs, or shRNAs. In one
embodiment, an inhibitor of a miR-15 family memberis an
inhibitory RNA molecule comprising a double-stranded
region, wherein the double-stranded region comprises a
sequence having 100% identity and complementarity to a
mature sequence of a miR-15 family member (e.g. SEQ ID
NOs: 7, 9, 11, 14, 16, and 20). In another embodiment, an
inhibitor of a miR-115 family memberis an inhibitor RNA
molecule comprising a double-stranded region, wherein the
double-stranded region comprises a sequence having 100%
identity and complementarity to a star sequence of a miR-15
family member(e.g. SEQ ID NOs:8, 10, 12, 13, 15, 17, and
21). In some embodiments, inhibitors ofone or more miR-15
family members are inhibitory RNA molecules which com-
prise a double-stranded region, wherein said double-stranded
region comprises a sequence of at least about 75%, 80%,
85%, 90%, 95%, 96%, 97%, 98%, or 99% identity and
complementarity to a mature sequence of one or more miR-
15 family members.
Multiple members of the miR-15 family (e.g. miR-15a,
miR-15b, miR-16-1, miR-16-2, miR-195, miR-424, and
miR-497) maybe inhibited simultaneously by administering
multiple inhibitors, wherein each inhibitor targets a separate
miR-15 family member. For example, in some embodiments,
at least two membersof the miR-15 family are inhibited by
administering two separate inhibitors. In other embodiments,
at least three members of the miR-15 family are inhibited by
administering three separate inhibitors. In still other embodi-
ments, at least four members of the miR-15 family are inhib-
ited by administering four separate inhibitors. In further
embodiments,at least five members ofthe miR-15 family are
inhibited by administering five separate inhibitors. In one
embodiment,all six members ofthe miR-15 family are inhib-
ited by administering six separate inhibitors.
In another embodiment, an inhibitor of miR-15 family
function is a nucleic acid comprising one or more miR-15
binding sites. The seed region (AGCAGCAC; SEQ ID NO:
18) of all the miR-15 family membersis highly conserved.
Therefore, a nucleic acid comprising a binding site having
substantial complementarity to the miR-15 seed sequence
would bind all membersofthe miR-15 family. This approach
has been analogized to the use of a sponge to “soak up” the
effective miR-15 family members, thereby reducing the over-
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all pool ofmiRNAsthat could impacta given target sequence.
The term “miR-15 binding site” as used herein refers to a
nucleotide sequence that is capable of binding a mature
sequence of miR-15a, miR-15b, miR-16-1, miR-16-2, miR-
195, miR-424, miR-497, or combinationsthereof. Preferably,
a miR-15 binding site comprises a sequence that is substan-
tially complementary to the miR-15 seed sequence. The seed
sequence or seed region refers to nucleotides 2-8 of the 5'
portion ofthe mature miRNA sequence. In one embodiment,
the miR-15 binding site comprises a sequencethat is substan-
tially complementary to SEQ ID NO: 18. The inhibitory
nucleic acid comprising one or more miR-15 bindingsites
may be from about 20 to about 500 nucleotides in length,
about 25 to about 400 nucleotides in length, about 30 to about
300 nucleotides in length, about 40 to about 200 nucleotides
in length, or about 50 to about 100 nucleotides in length. For
example, the nucleic acid may be 20, 21, 22, 23, 24, 25, 26,
27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95,
100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 225,
250, 275, 300, 350, 400, 500 nucleotides in length. The
nucleic acid may contain 1, 2,3, 4, 5, 6, 7, 8, 9, 10, 12, 15, or
20 miR-15 binding sites. The multiple ma-15 bindingsites
may be adjacent or may be separated by spacers of 1, 2, 3, 4,
5, 6, 7, 8, 9, 10 or more nucleotides.
In another embodiment, an expression vector may be used
to deliveran inhibitor ofone ormore miR-15 family members
to a cell or subject. A “vector” is a composition of matter
which can be used to deliver a nucleic acid ofinterest to the
interior of a cell. Numerous vectors are known in the art
including, but not limited to, linear polynucleotides, poly-
nucleotides associated with ionic or amphiphilic compounds,
plasmids, and viruses. Thus, the term “vector” includes an
autonomously replicating plasmid or a virus. Examples of
viral vectors include, but are not limited to, adenoviral vec-
tors, adeno-associated virus vectors, retroviral vectors, and
the like. An expression construct can bereplicated in a living
cell, or it can be made synthetically. For purposes of this
application, the terms “expression construct,” “expression
vector,” and “vector,” are used interchangeably to demon-
strate the application ofthe invention in a general, illustrative
sense, and are not intended to limit the invention.
In one embodiment, an expression vector for expressing an
inhibitor ofone or more miR-15 family members comprises a
promoter operably linked to a polynucleotide encoding an
antisense oligonucleotide, wherein the sequence of the
expressed antisense oligonucleotide is partially or perfectly
complementary to a mature sequence ofone or more miR-15
family members. The phrase “operably linked” or “under
transcriptional control” as used herein meansthat the pro-
moteris in the correct location andorientation in relation to a
polynucleotide to control the initiation of transcription by
RNA polymerase and expression of the polynucleotide. In
another embodiment, an expression vector for expressing an
inhibitor of one or more miR-15 family members comprises
one or more promoters operably linked to a polynucleotide
encoding a shRNAor siRNA, wherein the expressed shRNA
or siRNA comprises a double stranded regionthatis identical
and complementary or partially identical and partially
complementary to a mature sequence ofone or more miR-15
family members. “Partially identical and partially comple-
mentary”refers to a sequencethatis at least about 75%, 80%,
85%, 90%, 95%, 96%, 97%, 98%, or 99% identical and
complementary to a target polynucleotide sequence.
In certain embodiments, the nucleic acid encoding a poly-
nucleotide of interest is under transcriptional control of a
promoter.A “promoter”refers toa DNA sequence recognized
by the synthetic machinery ofthecell, or introduced synthetic
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machinery, required to initiate the specific transcription of a
gene. The term promoterwill be used hereto refer to a group
of transcriptional control modules that are clustered around
the initiation site for RNA polymeraseI, IT, or IT.
14
responseto specific physiologic signals can permit inducible
expression of the gene product. Tables 1 and 2 list several
regulatory elements that may be employed,in the context of
the present invention, to regulate the expression of the poly-
nucleotide of interest (e.g. inhibitor of miR-15 members).
 
. In some embodiments, the human cytomegalovirus (CMV) This list is not intended to be exhaustive of all the possibleimmediate early gene promoter, the SV40 early promoter, the : : . :- : : . elements involved in the promotion of gene expression but,Rous sarcoma virus long terminal repeat, rat insulin pro- merely, to be exemplary thereof.
moter, and glyceraldehyde-3-phosphate dehydrogenase pro- Below is a list of viral promoters, cellular promoters/en-moter can be used to obtain high-level expression of the io hancers and inducible promoters/enhancers that could be
coding sequenceofinterest. The use of other viral or mam- used in combination with the polynucleotide of interest in an
malian cellular or bacterial phage promoters which are well- expression construct (Table 1 and Table 2). Additionally, any
knownin the art to achieve expression ofa coding sequence of promoter/enhancer combination as per the Eukaryotic Pro-
interest is contemplated as well, provided that the levels of moter Data Base EPDB)couldalso be used to drive expres-
expression are sufficient for a given purpose. 15 sion of the gene. Eukaryotic cells can support cytoplasmic
By employing a promoter with well-knownproperties, the transcription from certain bacterial promotersifthe appropri-
level and pattern ofexpression ofthe polynucleotideofinter- ate bacterial polymerase is provided, either as part of the
est following transfection or transformation can be opti- delivery complex or as an additional genetic expression con-
mized. Further, selection of a promoter that is regulated in struct.
TABLE 1
Promoter and/or Enhancer
Promoter/Enhancer References
Immunoglobulin Heavy Chain
Immunoglobulin Light Chain
T-Cell Receptor
HLA DQ aand/or DQ 6
§-Interferon
Interleukin-2
Interleukin-2 Receptor
MHCClass II 5
MHCClass III HLA-DRa
f-Actin
Muscle Creatine Kinase (MCK)
Prealbumin (Transthyretin)
Banerji et al., 1983; Gilles et al., 1983; Grossched|
et al., 1985; Atchinsonet al., 1986, 1987; Imler
et al., 1987; Weinbergeret al., 1984; Kiledjian
et al., 1988; Porton et al.; 1990
Queenet al., 1983; Picard et al., 1984
Luriaet al., 1987; Winoto et al., 1989; Redondo
et al.; 1990
Sullivan et al., 1987
Goodbournet al., 1986; Fujita et al., 1987;
Goodbourn etal., 1988
Greeneet al., 1989
Greeneet al., 1989; Lin et al., 1990
Kochet al., 1989
Sherman etal., 1989
Kawamotoet al., 1988; Ng etal.; 1989
Jaynes et al., 1988; Horlick et al., 1989; Johnson
et al., 1989
Costaet al., 1988
Elastase I Ornitz et al., 1987
Metallothionein (MTII) Karin et al., 1987; Culottaet al., 1989
Collagenase Pinkert et al., 1987; Angel et al., 1987a
Albumin Pinkert et al., 1987; Troncheet al., 1989, 1990
a-Fetoprotein Godboutet al., 1988; Campereet al., 1989
t-Globin Bodineet al., 1987; Perez-Stableet al., 1990
6-Globin Trude et al., 1987
c-fos Cohenet al., 1987
c-HA-ras Triesman, 1986; Deschampset al., 1985
Insulin Edlundet al., 1985
Neural Cell Adhesion Molecule(NCAM)
q,-Antitrypain
H2B (TH2B) Histone
Mouseand/or Type I Collagen
Glucose-Regulated Proteins
Hirshet al., 1990
Latimeret al., 1990
Hwanget al., 1990
Ripeet al., 1989
Changet al., 1989(GRP94 and GRP78)
Rat Growth Hormone
Human Serum Amyloid A (SAA)
Troponin I (TN I)
Platelet-Derived Growth Factor(PDGF)
Duchenne Muscular Dystrophy
SV40
Polyoma
Larsenet al., 1986
Edbrookeetal., 1989
Yutzey et al., 1989
Pechet al., 1989
Klamutet al., 1990
Banerji et al., 1981; Moreauet al., 1981; Sleigh et
al., 1985; Firak et al., 1986; Herr et al., 1986;
Imbraet al., 1986; Kadeschet al., 1986; Wang et
al., 1986; Ondeket al., 1987; Kuhlet al., 1987;
Schaffner et al., 1988
Swartzendruberet al., 1975; Vasseuret al., 1980;
Katinkaet al., 1980, 1981; Tyndell et al., 1981;
Dandolo et al., 1983; de Villiers et al., 1984; Hen
et al., 1986; Satake et al., 1988; Campbell and/or
Villarreal, 1988
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Promoter and/or Enhancer
Promotetr/Enhancer References
Retroviruses Kriegler et al., 1982, 1983; Levinson et al., 1982;
Kriegler et al., 1983, 1984a, b, 1988; Boszeet al.,
1986; Miksicek et al., 1986; Celanderet al., 1987;
Thiesen et al., 1988; Celanderet al., 1988; Choi
et al., 1988; Reisman et al., 1989
Papilloma Virus Campoet al., 1983; Lusky et al., 1983; Spandidos
and/or Wilkie, 1983; Spalholz et al., 1985; Lusky
et al., 1986; Cripe et al., 1987; Gloss et al., 1987;
Hirochika et al., 1987; Stephenset al., 1987
Hepatitis B Virus Bulla et al., 1986; Jameelet al., 1986; Shauletal.,
1987; Spandauet al., 1988; Vannice et al., 1988
Human Immunodeficiency Virus Muesinget al., 1987; Hauberet al., 1988;
Jakobovits et al., 1988; Feng et al., 1988; Takebe
et al., 1988; Rosen etal., 1988; Berkhoutet al.,
1989; Laspia et al., 1989; Sharp etal., 1989;
Braddocketal., 1989
Cytomegalovirus (CMV)
et al., 1986
Gibbon Ape Leukemia Virus Holbrooketal., 1987; Quinn et al., 1989
Weberet al., 1984; Boshart et al., 1985; Foecking
 
TABLE 2
Inducible Elements
Element Inducer References
MT II Phorbol Ester (TFA) Palmiter et al., 1982;
Heavy metals Haslinger et al., 1985;
Searle et al., 1985; Stuart
et al., 1985; Imagawa
et al., 1987, Karin et al.,
1987; Angelet al., 1987b;
McNeall et al., 1989
MMTV (mouse Glucocorticoids Huanget al., 1981; Lee
mammary tumorvirus) et al., 1981; Majors etal.,
1983; Chandleret al.,
1983; Ponta et al., 1985;
Sakaiet al., 1988
§-Interferon poly(@)x Tavernieret al., 1983
poly(re)
Adenovirus 5 E2 EIA Imperiale et al., 1984
Collagenase Phorbol Ester (TPA) Angelet al., 1987a
Stromelysin Phorbol Ester (TPA) Angel et al, 1987b
SV40 Phorbol Ester (TPA) Angelet al., 1987b
Murine MX Gene Interfron, Newcastle Huget al., 1988
Disease Virus
GRP78 Gene A23187 Resendezet al., 1988
a-2-Macroglobulin IL-6 Kunzet al., 1989
Vimentin Serum Rittling et al., 1989
MHCClass I Gene Interferon Blanar et al., 1989
H-2kb
HSP70 EIA, SV40 Large T Tayloret al., 1989, 1990a,
Antigen 1990b
Proliferin Phorbol Ester-TPA Mordacq et al., 1989
Tumor Necrosis Factor PMA Henselet al., 1989
Thyroid Stimulating Thyroid Hormone Chatterjee et al., 1989
Hormone a@ Gene
 
Ofparticular interest are muscle specific promoters, and
moreparticularly, cardiac specific promoters. These include
the myosin light chain-2 promoter (Franz etal., 1994; Kelly et
al., 1995), the alpha actin promoter (Mossetal., 1996), the
troponin 1 promoter (Bhaysar et al., 1996); the Na*/Ca?*
exchanger promoter (Barnes et al., 1997), the dystrophin
promoter (Kimuraet al., 1997), the alpha7 integrin promoter
(Ziober and Kramer, 1996), the brain natriuretic peptide pro-
moter (LaPointe etal., 1996) and the alpha B-crystallin/small
heat shock protein promoter (Gopal-Srivastava, 1995), alpha
myosin heavy chain promoter (Yamauchi-Takihara et al.,
1989) and the ANF promoter (LaPointe etal., 1988).
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A polyadenylation signal may be includedto effect proper
polyadenylation of the gene transcript where desired. The
nature of the polyadenylation signal is not believed to be
crucial to the successful practice of the invention, and any
such sequence may be employed such as human growth hor-
mone and SV40polyadenylation signals. Also contemplated
as an elementofthe expression cassette is a terminator. These
elements can serve to enhance message levels and to mini-
mize read through from the cassette into other sequences.
In certain embodimentsofthe invention, the cells contain-
ing nucleic acid constructs ofthe present invention,a cell may
be identified in vitro or in vivo by including a marker in the
expression construct. Such markers would confer an identi-
fiable changeto the cell permitting easy identificationofcells
containing the expression construct. Usually the inclusion of
a drug selection markeraids in cloning andin the selection of
transformants, for example, genes that confer resistance to
neomycin, puromycin, hygromycin, DHFR, GPT, zeocin and
histidinol are useful selectable markers. Alternatively,
enzymes such as herpes simplex virus thymidine kinase (tk)
or chloramphenicol acetyltransferase (CAT) may be
employed. Immunologic markers also can be employed. The
selectable marker employedis not believed to be important,
so long as it is capable of being expressed simultaneously
with the nucleic acid encoding a gene product. Further
examples of selectable markers are well known to one of skill
in the art.
There are a numberof ways in which expression vectors
may be introducedinto cells. In certain embodiments of the
invention, the expression construct comprises a virus or engi-
neered construct derived from a viral genome. Theability of
certain viruses to enter cells via receptor-mediated endocyto-
sis, to integrate into host cell genomeandexpressviral genes
stably andefficiently have made them attractive candidates
for the transfer offoreign genes into mammaliancells (Ridge-
way, 1988; Nicolas and Rubenstein, 1988; Baichwal and
Sugden, 1986; Temin, 1986).
Oneofthe preferred methodsfor in vivo delivery involves
the use of an adenovirus expression vector. “Adenovirus
expression vector” is meant to include those constructs con-
taining adenovirus sequencessufficient to (a) support pack-
aging of the construct and (b) to express an antisense poly-
nucleotide (or other inhibitory polynucleotide) that has been
clonedtherein. The expression vector comprises a genetically
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engineered for ofadenovirus, Knowledgeofthe genetic orga-
nization ofadenovirus, a 36 kB,linear, double-stranded DNA
virus, allows substitution of large pieces of adenoviral DNA
with foreign sequences up to 7 kB (Grunhaus and Horwitz,
1992). In contrast to retrovirus, the adenoviral infection of
host cells does not result in chromosomalintegration because
adenoviral DNA canreplicate in an episomal manner without
potential genotoxicity. Also, adenoviruses are structurally
stable, and no genomerearrangementhas been detectedafter
extensive amplification. Adenovirus can infect virtually all
epithelial cells regardless of their cell cycle stage.
Adenovirusis particularly suitable for use as a gene trans-
fer vector because of its mid-sized genome, ease of manipu-
lation, high titer, wide target cell range and high infectivity.
Both ends of the viral genome contain 100-200 base pair
inverted repeats (ITRs), which are cis elements necessary for
viral DNA replication and packaging.
Other than the requirement that the adenovirus vector be
replication defective, or at least conditionally defective, the
nature ofthe adenovirus vector1s not believed to be crucial to
the successful practice of the invention. The adenovirus may
be of any of the 42 different known serotypes or subgroups
A-F. Adenovirus type 5 ofsubgroup C is the preferred starting
material in order to obtain the conditional replication-defec-
tive adenovirus vector for usein the present invention. Thisis
because Adenovirus type 5 is a human adenovirus about
which a great deal of biochemical and genetic information is
known, andit has historically been used for most construc-
tions employing adenovirus as a vector.
The typical vector according to the present invention is
replication defective and will not have an adenovirus E1
region. Thus, it will be most convenient to introduce the
polynucleotide encoding the gene ofinterest at the position
from which the El-coding sequences have been removed.
However, the position of insertion ofthe construct within the
adenovirus sequences is not critical to the invention. The
polynucleotide encoding the gene of interest may also be
inserted in lieu of the deleted E3 region in E3 replacement
vectors, as described by Karlssonet al. (1986), or in the E4
region where a helpercell line or helper virus complements
the E4 defect.
Adenovirus vectors have been used in eukaryotic gene
expression (Levrero et al., 1991; Gomez-Foix et al., 1992)
and vaccine development (Grunhausand Horwitz, 1992; Gra-
ham and Prevec, 1991). Recently, animal studies suggested
that recombinant adenovirus could be used for gene therapy
(Stratford-Perricaudet and Perricaudet, 1991; Stratford-Per-
ricaudet, et al., 1990; Rich et al., 1993), Studies in adminis-
tering recombinant adenovirus to different tissues include
trachea instillation (Rosenfeld et al., 1991; Rosenfeld et al.,
1992), muscle injection (Ragotet al., 1993), peripheral intra-
venous injections (Herz and Gerard, 1993) and stereotactic
inoculation into the brain (Le Gal La Salle et al., 1993).
Retroviral vectors are also suitable for expressing inhibi-
tors ofmiR-15 family membersin cells. The retroviruses are
a group of single-stranded RNA viruses characterized by an
ability to convert their RNA to double-stranded DNA in
infected cells by a process of reverse-transcription (Coffin,
1990). The resulting DNAthenstably integrates into cellular
chromosomes as a provirus and directs synthesis of viral
proteins. The integration results in the retention of the viral
gene sequencesin the recipient cell and its descendants. The
retroviral genomecontainsthree genes, gag, pol, and env that
code tier capsid proteins, polymerase enzyme, and envelope
components, respectively. A sequence found upstream from
the gag gene contains a signal for packaging of the genome
into virions. Two long terminal repeat (LTR) sequences are
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presentat the 5' and 3' ends ofthe viral genome.These contain
strong promoter and enhancer sequences and are also
required for integration in the host cell genome (Coffin,
1990).
In order to construct a retroviral vector, a nucleic acid
encoding a geneofinterestis insertedinto the viral genome in
the place of certain viral sequences to produce a virusthatis
replication-defective. In order to produce virions, a packag-
ing cell line containing the gag,pol, and env genes but without
the LTR and packaging components is constructed (Mann et
al., 1983). When a recombinant plasmid containing a cDNA,
together with the retroviral LTR and packaging sequencesis
introduced into this cell line (by calctum phosphate precipi-
tation for example), the packaging sequence allows the RNA
transcript of the recombinant plasmid to be packaged into
viral particles, which are then secreted into the culture media
(Nicolas and Rtibenstein, 1988; Temin, 1986; Mann etal.,
1983). The media containing the recombinantretrovirusesis
then collected, optionally concentrated, and used for gene
transfer. Retroviral vectors are able to infect a broad variety of
cell types. However, integration and stable expression require
the division of host cells (Paskindet al., 1975).
Other viral vectors may be employed as expression con-
structs in the present invention. Vectors derived from viruses
such as vaccinia virus (Ridgeway, 1988; Baichwal and Sug-
den, 1986; Coupar et al., 1988) adeno-associated virus (AAV)
(Ridgeway, 1988; Baichwal and Sugden, 1986; Hermonat
and Muzycska, 1984) and herpesviruses may be employed.
They offer several attractive features for various mammalian
cells (Friedmann, 1989; Ridgeway, 1988; Baichwal and Sug-
den, 1986; Couparet al., 1988; Horwichetal., 1990).
In order to effect expression of sense or antisense gene
constructs, the expression construct must be delivered into a
cell. This delivery may be accomplishedin vitro, as in labo-
ratory procedures for transformingcells lines, or in vivo or ex
vivo, as in the treatment ofcertain disease states. One mecha-
nism for delivery is via viral infection where the expression
construct is encapsidated in an infectious viral particle.
Several non-viral methods for the transfer of expression
constructs into cultured mammalian cells also are contem-
plated by the present invention. These include calcium phos-
phate precipitation (Graham andVan Der Eb, 1973; Chen and
Okayama, 1987; Rippeet al., 1990) DEAE-dextran (Gopal,
1985), electroporation (Tur-Kaspaet al., 1986; Potteret al.,
1984), direct microinjection (Harland and Weintraub, 1985),
DNA-loaded liposomes (Nicolau and Sene, 1982; Fraley et
al., 1979) and lipofectamine-DNA complexes,cell sonication
(Fechheimer et al., 1987), gene bombardment using high
velocity microprojectiles (Yang et al., 1990), and receptor-
mediated transfection (Wu and Wu, 1987; Wu and Wu,1988).
Someofthese techniques may be successfully adapted for in
Vivo or ex Vivo use.
Once the expression construct has been delivered into the
cell the nucleic acid encoding the gene of interest may be
positioned and expressedatdifferent sites. In certain embodi-
ments, the nucleic acid encoding the gene may be stably
integrated into the genomeofthe cell. This integrationmay be
in the cognate location and orientation via homologous
recombination (gene replacement)or it may be integrated in
a random, non-specific location (gene augmentation). In yet
further embodiments, the nucleic acid may be stably main-
tained in the cell as a separate, episomal segment of DNA.
Such nucleic acid segments or “episomes” encode sequences
sufficient to permit maintenance andreplication independent
of or in synchronization with the host cell cycle. How the
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expression constructis delivered to a cell andwhere in the cell
the nucleic acid remains is dependent on the type of expres-
sion construct employed.
In another embodiment of the invention, the expression
construct may simply consist ofnaked recombinant DNA or
plasmids. Transfer ofthe construct may be performed by any
of the methods mentioned above which physically or chemi-
cally permeabilize the cell membrane. This is particularly
applicable for transfer in vitro but it may be applied to in vivo
use as well. Dubensky et al. (1984) successfully injected
polyomavirus DNAinthe form ofcalcium phosphate precipi-
tates into liver and spleen of adult and newborn mice demon-
strating active viral replication and acute infection. Ben-
venisty and Neshif (1986) also demonstrated that direct
intraperitoneal injection of calctum phosphate-precipitated
plasmids results in expression of the transfected genes, it is
envisioned that DNA encoding a polynucleotide of interest
may also be transferred in a similar manner in vivo and
express the gene product.
In still another embodimentof the invention for transfer-
ring anakedDNA expression construct into cells may involve
particle bombardment. This method depends onthe ability to
accelerate DNA-coated microprojectiles to a high velocity
allowing them to pierce cell membranesandenter cells with-
out killing them (Klein et al. 1987). Several devices for accel-
erating small particles have been developed. One such device
relies on a high voltage discharge to generate an electrical
current, which in turn provides the motive force (Yanget al.,
1990). The microprojectiles used have consisted of biologi-
cally inert substances such as tungsten or gold beads.
Selected organs includingthe liver, skin, and muscle tissue
of rats and mice have been bombarded in vivo (Yanget al.,
1990; Zelenin et al., 1991). This may require surgical expo-
sure of the tissueor cells, to eliminate any intervening tissue
between the gun andthe target organ, i.e., ex vivo treatment.
Again, DNA encodinga particular polynucleotide of interest
maybedelivered via this method andstill be incorporated by
the present invention.
In a further embodiment of the invention, the expression
construct may be entrapped in a liposome. Liposomes are
vesicular structures characterized by a phospholipid bilayer
membraneand an inner aqueous medium. Multilamellarlipo-
somes have multiple lipid layers separated by aqueous
medium. They form spontaneously when phospholipids are
suspended in an excess of aqueous solution. The lipid com-
ponents undergo self-rearrangement before the formation of
closed structures and entrap water and dissolved solutes
between the lipid bilayers (Ghosh and Bachhawat, 1991).
Also contemplated are lipofectamine-DNA complexes.
In certain embodimentsofthe invention,the liposome may
be complexed with a hemagglutinating virus (HVJ). This has
been shownto facilitate fusion with the cell membrane and
promote cell entry of liposome-encapsulated DNA (Kaneda
et al., 1989). In other embodiments, the liposome may be
complexed or employed in conjunction with nuclear non-
histone chromosomalproteins (HMG-1) (Kato et al., 1991).
In yet further embodiments, the liposome may be complexed
or employed in conjunction with both HVJ and HMG-1. In
that such expression constructs have been successfully
employed in transfer and expression of nucleic acid in vitro
and in vivo, then they are applicable for the present invention.
Where a bacterial promoter is employed in the DNA con-
struct, it also will be desirable to include within the liposome
an appropriate bacterial polymerase.
Other expression constructs which can be employed to
deliver a nucleic acid encoding a particular geneinto cells are
receptor-mediated delivery vehicles. These take advantage of
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the selective uptake ofmacromolecules by receptor-mediated
endocytosis in almostall eukaryotic cells. Because ofthecell
type-specific distribution of various receptors, the delivery
can be highly specific (Wu and Wu, 1993).
Receptor-mediated gene targeting vehicles generally con-
sist of two components: a cell receptor-specific ligand and a
DNA-binding agent. Several ligands have been used for
receptor-mediated gene transfer. The most extensively char-
acterized ligands are asialoorosomucoid (ASOR) (Wu and
Wu, 1987) and transferrin (Wagneret al., 1990). Recently, a
synthetic neoglycoprotein, which recognizes the same recep-
tor as ASOR,has been used as a gene delivery vehicle (Ferkol
et al., 1993; Perales et al., 1994) and epidermal growth factor
(EGF)hasalso been used to deliver genes to squamous car-
cinoma cells (Myers, EPO 0273085).
In other embodiments, the delivery vehicle may comprise a
ligand and a liposome. For example, Nicolau et al. (1987)
employed lactosyl-ceramide, a galactose-terminal asialgan-
glioside, incorporated into liposomes and observed an
increase in the uptake of the insulin gene by hepatocytes.
Thus, it is feasible that a nucleic acid encoding a particular
gene also maybespecifically delivered into a cell type (e.g.
cardiac cell) by any numberofreceptor-ligand systems with
or without liposomes. For example, epidermal growth factor
(EGF) maybeusedas the receptor for mediated delivery of a
nucleic acid into cells that exhibit upregulation ofEGF recep-
tor. Mannosecan be usedto target the mannose receptor on
liver cells. Also, antibodies to CD5 (CLL), CD22 (ym-
phoma), CD25 leukemia) and MAA (melanoma) can simi-
larly be used as targeting moieties.
In aparticularexample, the polynucleotide may be admin-
istered in combination with a cationic lipid. Examples of
cationic lipids include, but are not limited to, lipofectin,
DOTMA, DOPE, and DOTAP. The publication of
W00071096, whichis specifically incorporated by reference,
describes different formulations, such as a DOTAP:choles-
terol or cholesterol derivative formulation that can effectively
be used for gene therapy. Other disclosures also discuss dif-
ferent lipid or liposomal formulations including nanopar-
ticles and methods of administration; these include, but are
not limited to, U.S. Patent Publication 20030203865,
20020150626, 20030032615, and 20040048787, which are
specifically incorporated by reference to the extent they dis-
close formulations and other related aspects ofadministration
and delivery of nucleic acids. Methods used for forming
particles are also disclosed in U.S. Pat. Nos. 5,844,107, 5,877,
302, 6,008,336, 6,077,835, 5,972,901, 6,200,801, and 5,972,
900, which are incorporated by reference for those aspects.
In certain embodiments, gene transfer may more easily be
performed under ex vivo conditions. Ex vivo gene therapy
refers to the isolation of cells from an animal, the delivery of
a nucleic acid into the cells in vitro, and then the return ofthe
modified cells back into an animal. This may involve the
surgical removalof tissue/organs from an animalorthe pri-
mary culture of cells andtissues.
The present invention also includes methods for scaveng-
ing or clearing inhibitors ofmiR-15 family members follow-
ing treatment. The method may comprise overexpressing
hybridization sites for inhibitors of the miR-15 family mem-
bers in cardiac tissue. In one embodiment, the method com-
prises overexpression of hybridization sites for inhibitors of
the miR-15 family members in cardiac muscle using a heart
muscle specific promoter (e.g. a-MHC).In another embodi-
ment, the hybridization site may comprise a sequence of a
seed region from a miR-15 family member. In another
embodiment, the hybridization site may comprise the
sequence of SEQ ID NO: 18. In some embodiments, the
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hybridization site may contain a sequencethat is complemen-
tary to a sequence from the 3'UTRofone or moretargets of a
miR-15 family member, such as FGF2, TGFb-inducedfactor
2, BCL9I, BCL2L, CDC25A,cyclin E1, cyclin D1, or cyclin
D2.
In another embodimentofthe invention, an inhibitor ofone
or more miR-15 family members is administered to the sub-
ject in combination with other therapeutic modalities. Cur-
rent medical managementof cardiac hypertrophy in theset-
ting of a cardiovascular disorder includes the use of at least
twotypes ofdrugs: inhibitors ofthe renin-angiotensin system
and B-adrenergic blocking agents (Bristow, 1999). Therapeu-
tic agents to treat pathologic hypertrophy in the setting of
heart failure include angiotensin IT converting enzyme (ACE)
inhibitors and B-adrenergic receptor blocking agents (Eich-
horn and Bristow, 1996). Other pharmaceutical agents that
have been disclosed for treatment of cardiac hypertrophy
include angiotensin II receptor antagonists (U.S. Pat. No.
5,604,251) and neuropeptideY antagonists (WO 98/33791).
Non-pharmacological treatment is primarily used as an
adjunct to pharmacological treatment. One means of non-
pharmacological treatment involves reducing the sodium in
the diet. In addition, non-pharmacological treatment also
entails the elimination of certain precipitating drugs, includ-
ing negative inotropic agents (e.g., certain calcium channel
blockers and antiarrhythmic drugs like disopyramide), car-
diotoxins (e.g., amphetamines), and plasma volume expand-
ers (e.g., nonsteroidal anti-inflammatory agents and gluco-
corticoids).
Thus,in additionto the therapies described above, one may
also provide to the subject more “standard” pharmaceutical
cardiac therapies with the inhibitor of one or more miR-15
family members. Examples of other therapies include, with-
out limitation, so-called “beta blockers,” anti-hypertensives,
cardiotonics, anti-thrombotics, vasodilators, hormone
antagonists, iontropes, diuretics, endothelin receptor antago-
nists, calcium channel blockers, phosphodiesterase inhibi-
tors, ACE inhibitors, angiotensin type 2 antagonists and
cytokine blockers/inhibitors, and FIDAC inhibitors. The
combination therapy also may involve inhibiting the expres-
sion or activity of additional miRNAsinvolved in cardiac
remodeling such as miR-499, miR-208, miR-208b and miR-
21. Combination therapy may also include overexpression of
particular microRNAs, such as miR-29.
Combinations maybe achieved by contacting cardiac cells
with a single composition or pharmacological formulation
that includes an inhibitor of one or more miR-15 family
membersanda standard pharmaceutical agent, or by contact-
ing the cell with two distinct compositions or formulations,at
the same time, wherein one composition includes the inhibi-
tor of a miR-15 family memberand the other includes the
standard pharmaceutical agent. Alternatively, the therapy
using an inhibitor ofa miR-15 family member mayprecede or
follow administration of the other agent(s) by intervals rang-
ing from minutes to weeks. In embodiments where the stan-
dard pharmaceutical agent and the inhibitor of a miR-15
family memberare applied separately to the cell, one would
generally ensure that a significant period of time did not
expire between the time of each delivery, such that the phar-
maceutical agent and inhibitor of a miR-15 family member
would still be able to exert an advantageously combined
effect on the cell. In such instances, it is contemplated that one
would typically contact the cell with both modalities within
about 12-24 hours of each other and, morepreferably, within
about 6-12 hours ofeach other, with a delay time ofonly about
12 hours being mostpreferred. In somesituations, it may be
desirable to extend the timeperiodfor treatmentsignificantly,
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however, where several days (2, 3, 4, 5, 6 or 7) to several
weeks (1, 2, 3, 4, 5, 6, 7 or 8) lapse between the respective
administrations.
It also is conceivable that more than one administration of
either an inhibitor of a miR-15 family member, or the other
pharmaceutical agent will be desired. In this regard, various
combinations may be employed. By way of illustration,
wherethe inhibitor ofamiR-15 family memberis “A” and the
other pharmaceutical agent is “B,” the following permuta-
tions based on 3 and4 total administrations are exemplary:
A/B/A B/A/B B/B/A A/A/B B/A/A A/B/B B/B/B/A B/B/
A/B
A/A/B/B A/B/A/B A/B/B/A B/B/A/A B/A/B/A B/A/A/B
B/B/B/A
A/A/A/B B/A/A/A A/B/A/A A/A/B/A A/B/B/B B/A/B/B
B/B/A/B
Other combinationsare likewise contemplated.
Treatment regimens would vary depending on the clinical
situation. However, long-term maintenance would appearto
be appropriate in most circumstances.It also may be desirable
to treat hypertrophy with inhibitors of miR-15 family mem-
bers intermittently, such as within a brief window during
disease progression.
Pharmacological therapeutic agents and methods of
administration, dosages, etc., are well knowntothoseof skill
in the art (see for example, the “Physicians Desk Reference”,
Kiaassen’s “The Pharmacological Basis of Therapeutics”,
“Remington’s Pharmaceutical Sciences”, and “The Merck
Index, Eleventh Edition”, incorporated herein by reference in
relevant parts), and may be combined with the invention in
tight ofthe disclosures herein. Somevariation in dosage will
necessarily occur depending on the condition of the subject
being treated. The person responsible for administration will,
in any event, determine the appropriate dose for the individual
subject, and such individual determinations are within the
skill of those of ordinary skill in the art.
Non-limiting examples of a pharmacological therapeutic
agent that may be used in the present invention include an
antihyperlipoproteinemic agent, an antiarteriosclerotic agent,
an antithrombotic/fibrinolytic agent, a blood coagulant, an
antiarrhythmic agent, an antihypertensive agent, a vasopres-
sor, a treatment agent for congestive heart failure,an antiangi-
nal agent, an antibacterial agent or a combination thereof.
In addition, it shouldbe noted that any ofthe following may
be used to develop newsets of cardiac therapy target genes as
B-blockers were used in the present examples (see below).
White it is expected that many of these genes may overlap,
new genetargets likely can be developed.
In certain embodiments, administration of an agent that
lowers the concentration of one of more blood lipids and/or
lipoproteins, knownherein as an “antihyperlipoproteinernic,”
may be combined with a cardiovascular therapy according to
the present invention, particularly in treatmentofatlierselero-
sis and thickenings or blockages ofvascular tissues. In certain
embodiments, an antihyperlipoproteinemic agent may com-
prise an aryloxyalkanoic/fibric acid derivative, a resin/bite
acid sequesterant, a HMG CoA reductase inhibitor, a nico-
tinic acid derivative, a thyroid hormoneor thyroid hormone
analog, a miscellaneous agent or a combination thereof
examples of aryloxyalkanoic/fibric acid derivatives include
beclobrate, enzafibrate, binifibrate, ciprofibrate, clinofibrate,
clofibrate (atromide-S), clofibric acid, etofibrate, fenofibrate,
gemfibrozil (lobid), nicofibrate, pirifibrate, ronifibrate, sim-
fibrate and theofibrate. Non-limiting examplesof resins/bile
acid sequesterants include cholestyramine (cholybar, ques-
tran), colestipol (colestid) and polidexide. Non-limiting
examples ofHMG CoAreductase inhibitors include lovasta-
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tin (mevacor), pravastatin (pravochol) or simvastatin (zocor).
Non-limiting examples of nicotinic acid derivatives include
nicotinate, acepimox, niceritrol, nicoclonate, nicomol and
oxiniacic acid. Non-limiting examples of thyroid hormones
and analogs thereof include etoroxate, thyropropic acid and
thyroxine.
Non-limiting examples of miscellaneous antihyperlipo-
proteinemics include acifran, azacosterol, benfluorex, f-ben-
zalbutyramide, camitine, chondroitin sulfate, clomestrone,
detaxtran, dextran sulfate sodium, 5,8,11,14,17-eicosapen-
taenoic acid, eritadenine, furazabol, megiutol, melinamide,
mytatrienediol, ornithine, y-oryzanol, pantethine, pentaeryth-
ritol tetraacetate, a-phenylbutyramide, pirozadil, probucol
(oreico), B-sitosterol, sultosilic acid-piperazine salt, tiad-
enol, triparanol and xenbucin. A non-limiting example of an
antiarteriosclerotic includes pyridinol carbamate.
In certain embodiments, administration of an agent that
aids in the removal or prevention of blood clots may be
combined with administration of a modulator, particularly in
treatment of athersclerosis and vasculature (e.g., arterial)
blockages. Non-limiting examples of antithrombotic and/or
fibrinolytic agents include anticoagulants, anticoagulant
antagonists, antiplatelet agents, thrombolytic agents, throm-
bolytic agent antagonists or combinationsthereof. In certain
embodiments, antithrombotic agents that can be administered
orally, such as, for example, aspirin and wafarin (coumadin),
are preferred.
Non-limiting examples of anticoagulants include aceno-
coumarol, ancrod, anisindione, bromindione, clorindione,
cournetarol, cyclocumarol, dextran sulfate sodium, dicuma-
rol, diphenadione, ethyl biscoumacetate, ethylidene dicou-
marol, fiuindione, heparin, hirudin, lyapolate sodium,
oxazidione, pentosan polysulfate, phenindione, phenproc-
ournon, phosvitin, picotamide, tioclomarol and warfarin.
Non-limiting examples of antiplatelet agents include aspi-
rin, a dextran, dipyridamole (persantin), heparin, sulfinpyra-
none(anturane) andticlopidine (fiend).
Non-limiting examples ofthrombolytic agents includetis-
sue plaminogen activator (activase), plasmin, pro-urokinase,
urokinase (abbokinase) streptokinase streptase), anistre-
plase/APSAC (eminase).
In certain embodiments wherein a patient is suffering from
a hemorrhageoran increased likelihood ofhemorrhaging, an
agent that may enhance blood coagulation may be used. Non-
limiting examples of blood coagulation promoting agents
include thrombolytic agent antagonists and anticoagulant
antagonists. Non-limiting examples of anticoagulant antago-
nists include protamine and vitamine K1.
Non-limiting examples of thrombolytic agent antagonists
include amiocaproic acid (amicar) and tranexamic acid (am-
stat). Non-limiting examples of antithrombotics include
anagrelide, argatroban, cilstazol, daltroban, defibrotide,
enoxaparin, fraxiparine, indobufen, lanioparan, ozagrel,
picotamide, plafibride, tedelparin,ticlopidine andtriflusal.
Non-limiting examples of antiarrhythmic agents include
Class I antiarrhythmic agents (sodium channel blockers),
Class II antiarrhythmic agents (beta-adrenergic blockers),
Class III antiarrhythmic agents (repolarization prolonging
drugs), Class IV antiarrhythmic agents (calcium channel
blockers) and miscellaneous antiarrhythmic agents.
Non-limiting examples of sodium channel blockers
include Class IA, Class IB and Class IC antiarrhythmic
agents. Non-limiting examples of Class IA antiarrhythmic
agents include disppyramide (norpace), procainamide (pron-
estyl) and quinidine (quinidex). Non-limiting examples of
ClassIB antiarrhythmic agents include lidocaine (xylocaine),
tocamide (tonocard) and mexiletine (mexitil). Non-limiting
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examples of Class IC antiarrhythmic agents include encam-
ide (enkaid) and flecamide (tambocor).
Non-limiting examples ofa beta Mocker, otherwise known
as a B-adrenergic blocker, a B-adrenergic antagonist or a Class
II antiarrhythmic agent, include acebutolol (sectral), alpre-
nolol, amosulalol, arotinolol, atenolol, befunolol, betaxolol,
bevantolol, bisoprolol, bopindolol, bucurnolol, bufetolol,
hufuralol, bunitrolol, bupranolol, butidrine hydrochloride,
butofilolol, carazolol, carteolol, carvedilol, celiprolol, ceta-
molol, cloranolol, dilevalol, epanolol, esmolol (brevibloc),
indenolol, labetalol, levobunolol, mepindolol, metipranolol,
metoprolol, moprolol, nadolol, nadoxolol, nifenalol,
nipradilol, oxprenolol, penbutolol, pindolol, practolol, prone-
thalol, propanolol (inderal), sotalol (betapace), sulfinalol,
tatinolot, tertatolol, timolol, toliprolol and xibinolol. In cer-
tain embodiments, the beta blocker comprises an aryloxypro-
panolamine derivative. Non-limiting examples of arylox-
ypropanolamine derivatives include acebutolol, alprenolol,
arotinolol, atenolol, betaxolol, bevantolol, bisoprolol, bopin-
dolol, bunitrolol, butofliolol, carazolol, carteolol, carveditol,
cetaniolol, epanolol, indenolol, mepindolol, metipranolol,
metoprolol, moprolol, nadolol, nipradilol, oxprenolol, penb-
utolol, pindolol, propanolol, talinolol, tertatolol, timolol and
toliprolol.
Non-limiting examples of an agent that prolong repolar-
ization, also known as a Class II antiarrhythmic agent,
include amiodarone (cordarone) and sotalol (betapace).
Non-limiting examples of a calcium channel blocker, oth-
erwise known as a Class IV antiarrythmic agent, include an
arylalkylamine(e.g., bepridile, diltiazem, fendiline, preny-
lamine, terodiline, verapamil), a dihydropyridine derivative
(felodipine, isradipine, nicardipine, nifedipine, nimodipine,
nisoldipine, nitrendipine) a piperazinde derivative (e.g., cin-
narizine, flunarizine, lidoflazine) or a micellaneous calcium
channel blocker such as bencyciane, etafenone, magnesium,
mibefradil or perhexyline. In certain embodiments a calcium
channel blocker comprises a long-acting dihydropyridine
(nifedipine-type) calcium antagonist.
Non-limiting examples of miscellaneous antiarrhythmic
agents include adenosine (adenocard), digoxin (lanoxin),
acecamide, ajmaline, amoproxan,aprindine, bretylium tosy-
late, bunaftine, butobendine, capobenic acid, cifenline, dis-
opyranide, hydroquinidine, indecainide, ipatropium bro-
mide, lidocaine, lorajmine, lorcainide, meobentine,
moricizine, pirmenol, prajmaline, propafenone, quinidine
polygalacturonate, quinidinesulfite and viquidil.
Non-limiting examples of antihypertensive agents include
sympatholytic, alpha/beta blockers, alpha blockers, anti-an-
giotensin II agents, beta blockers, calctum channel blockers,
vasodilators and miscellaneous antihypertensives.
Non-limiting examples of an alpha blocker, also known as
an a-adrenergic blocker or an a-adrenergic antagonist,
include amosulalol, arotinolol, dapiprazole, doxazosin,
ergoloid mesylates, fenspiride, indoramin, labetalol, nicer-
goline, prazosin, terazosin,tolazoline, trimazosin and yohim-
bine. In certain embodiments, an alpha blocker may comprise
a quinazoline derivative. Non-limiting examples of quinazo-
line derivatives include alfuzosin, bunazosin, doxazosin,pra-
zosin, terazosin and trimazosin. In certain embodiments, an
antihypertensive agent is both an alpha and beta adrenergic
antagonist. Non-limiting examples of an alpha/beta blocker
comprise labetalol (normodyne, trandate).
Non-limiting examples of anti-angiotensin I] agents
include angiotensin converting enzymeinhibitors and angio-
tensin II receptor antagonists, Non-limiting examples of
angiotensin converting enzyme inhibitors (ACE inhibitors)
include alacepril, enalapril (vasotec), captopril, cilazapril,
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delapril, enalaprilat, fosinopril lisinopril, moveltopril, perin-
dopril, quinapril and ramipril. Non limiting examples of an
angiotensin II receptor blocker, also knownas an angiotensin
II receptor antagonist, anANGreceptor blocker or anANG-II
type-1 receptor blocker (ARBS), include angiocandesartan,
eprosartan, irbesartan, losartan and valsartan.
Non-limiting examples of a sympatholytic include a cen-
trally acting sympatholytic or a peripherially acting sym-
patholytic. Non-limiting examples of a centrally acting sym-
patholytic, also known as an central nervous system (CNS)
sympatholytic, include clonidine (catapres), guanabenz
(wytensin) guanfacine (tenex) and methyldopa (aldomet).
Non-limiting examples of a peripherally acting sym-
patholytic include a ganglion blocking agent, an adrenergic
neuron blocking agent, a B-adrenergic blocking agent or a
alpha] -adrenergic blocking agent. Non-limiting examples of
a ganglion blocking agent include mecamylamine(inversive)
and trimethaphan (arfonad). Non-limiting examples of an
adrenergic neuron blocking agent include guanethidine(is-
melin) and reserpine (serpasil). Non-limiting examples of a
B-adrenergic blocker include acenitolol (sectral), atenolol
(tenormin), betaxolol (kerlone), carteolol (cartrol), labetalol
(normodyne,trandate), metoprolol (lopressor), nadanol(cor-
gard), penbutolol (levatol), pindolol (visken), propranolol
(inderal) and timolol (blocadren). Non-limiting examples of
alpha] -adrenergic blocker include prazosin (minipress), dox-
azocin (cardura) and terazosin (hytrin).
In certain embodiments a cardiovasculator therapeutic
agent may comprise a vasodilator(e.g., a cerebral vasodilator,
a coronary vasodilator or a peripheral vasodilator). In certain
preferred embodiments, a vasodilator comprises a coronary
vasodilator. Non-limiting examples of a coronary vasodilator
include amotriphene, bendazol, benfurodil hemisuccinate,
benziodarone, chloracizine, chromonar, clobenfurol, cloni-
trate, dilazep, dipyridamole, droprenilamine, efloxate, eryth-
rityl tetranitrane, etafenone, fendiline, floredil, ganglefene,
herestrol bis(B-diethylaminoethy! ether), hexobendine,itra-
min tosylate, khellin, mannitol hexanitrane, medibazine,
nicorglycerin, pentaerythritol tetranitrate, pentrinitrol, per-
hexyline, pirnefyl line, trapidil, tricromyl, trimetazidine,
troInitrate phosphate and visnadine.
In certain embodiments, a vasodilator may comprise a
chronic therapy vasodilator or a hypertensive emergency
vasodilator. Non-limiting examples of a chronic therapy
vasodilator include hydralazine (apresoline) and minoxidil
(oniten). Non-limiting examples of a hypertensive emer-
gency vasodilator include nitroprusside (nipride), diazoxide
(hyperstat IV), hydralazine (apresoline), minoxidil (loniten)
and verapamil.
Non-limiting examples of miscellaneous antihyperten-
sives include ajmaline, y-amindbutyric acid, bufeniode, cicle-
tainine, ciclosidomine, a cryptenamine tannate, fenoldopam,
flosequinan, ketanserin, mebutamate, mecamylamine, meth-
yldopa, methyl 4-pyridyl ketone thiosemicarbazone,
muzolimine, pargyline, pempidine, pinacidil, piperoxan, pri-
maperone, a protoveratrine, raubasine, rescimetol, ril-
menidene, saralasin, sodium nitrorusside, ticrynafen, tri-
methaphan camsylate, tyrosinase and urapidil.
Incertain embodiments, an antihypertensive may comprise
an arylethanolamine derivative, a benzothiadiazine deriva-
tive, a N-carboxyatkyl(peptide/lactam) derivative, a dihydro-
pyridine derivative, a guanidine derivative, a hydrazines/ph-
thalazine, an imidazole derivative, a quanternary ammonium
compound,a reserpine derivative or a suflonamidederivative.
Non-limiting examples of arylethanolamine derivatives
include amosulalol, bufuralol, dilevalol, labetalol, proneth-
alol, sotalol and sulfinalol. Non-limiting examples of ben-
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zothiadiazine derivatives include althizide, bendroflumethi-
azide, benzthiazide, benzylhydrochlorothiazide, buthiazide,
chlorothiazide, chlorthalidone, cyclopenthiazide, cyclothiaz-
ide, diazoxide, epithiazide, ethiazide, fenquizone, hydrochlo-
rothizide, hydroflumethizide, methyclothiazide, meticrane,
metolazone, paraflutizide, polythizide, tetrachlormethiazide
and trichlormethiazide. Non-limiting examples of N-car-
boxyalkyl(peptide/lactam) derivatives include alacepril, cap-
topril, cilazapril, delapril, enalapril, enalaprilat, fosinopril,
lisinopril, moveltipril, perindopril, quinapril and ramipril.
Non-limiting examples of dihydropyridine derivatives
include amlodipine, felodipine, isradipine, nicardipine, nife-
dipine, nilvadipine, nisoldipine and nitrendipine. Non-limit-
ing examples of guanidine derivatives include bethanidine,
debrisoquin, guanabenz, guanacline, guanadrel, guanazod-
ine, guanethidine, guanfacine, guanochlor, guanoxabenz and
guanoxan. Non-limiting examples of hydrazines/phthala-
zines include budralazine, cadralazine, dihydralazine,
endralazine, hydracarbazine, hydralazine, pheniprazine,
pildralazine and todralazine. Non-limiting examples of imi-
dazole derivatives include clonidine, lofexidine, phentola-
mine, tiamenidine and tolonidine. Non-limiting examples of
quanternary ammonium compoundsinclude azamethonium
bromide, chlorisondamine chloride, hexamethonium, penta-
cynium bis(methylsulfate), pentamethonium bromide, pento-
linium tartrate, phenactropinium chloride and trimethidinium
methosulfate. Non-limiting examples ofreserpine derivatives
include bietaserpine, deserpidine, rescinnamine, reserpine
and syrosingopine. Non-limiting examples of sulfonamide
derivatives include ambuside, clopamide, furosemide, inda-
pamide, quinethazone, tripamide and xipamide.
Vasopressors generally are used to increase blood pressure
during shock, which may occur during a surgical procedure.
Non-limiting examples of a vasopressor, also known as an
antihypotensive, include amezinium methyl] sulfate, angio-
tensin amide, ditnetofrine, dopamine, etifelmin, etilefrin,
gepefrine, metaraminol, midodrine, norepinephrine,
pholedrine and synephrine.
Non-limiting examples of agents for the treatment of con-
gestive heart failure include anti-angiotensin II agents, after-
load-preload reduction treatment, diuretics and inotropic
agents.
In certain embodiments, an animal patient that can not
tolerate an angiotensin antagonist may be treated with a com-
bination therapy. Such therapy may combine administration
of hydralazine (apresoline) and isosorbide dinitrate (isordil,
sorbitrate).
Non-limiting examples of a diuretic include a thiazide or
benzothiadiazine derivative (e.g., althiazide, bendroftumet-
hazide, benzthiazide, benzylhydrochlorothiazide, buthiazide,
chlorothiazide, chlorothiazide, chlorthalidone, cyclopenthi-
azide, epithiazide, ethiazide, ethiazide, fenquizone, hydro-
chlorothiazide, hydroflumethiazide, methyclothiazide, meti-
crane, metolazone, paraflutizide, polythizide,
tetrachlorornethiazide, trichlormethiazide), an organomercu-
rial (e.g., chlormerodrin, meralluride, mercamphamide, mer-
captomerin sodium, mercumallylic acid, mercumatilin
dodium, mercurouschloride, mersaly]), a pteridine(e.g., fur-
terene, triamterene), purines (e.g., acefylline, 7-morpholi-
nomethyltheophylline, protheobromine, theobromine), ste-
roids including aldosterone antagonists (e.g., canrenone,
oleandrin, spironolactone), a sulfonamide derivative (e.g.,
acetazolamide, ambuside, azosemide, bumetanide, butazola-
mide, chloraminophenamide, clofenamide, clorexolone,
diphenylmethane-4,4'-disulfonamide, disulfamide, ethox-
zolamide, furosemide, indapamide, mefruside, methazola-
mide, piretanide, quinethazone, torasemide, tripamide, xipa-
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mide), a uracil (e.g., aminometradine, amisometradine), a
potassium sparing antagonist(e.g., amiloride, triamterene) or
a miscellaneous diuretic such as aminozine, arbutin, chlora-
zanil, ethacrynic acid, etozolin, hydracarbazine, isosorbide,
mannitol, tnetochalcone, muzolimine, perhexyline, ticrnafen
and urea.
Non-limiting examples of a positive inotropic agent, also
known as a cardiotonic, include acefylline, an acetyldigi-
toxin, 2-amino-4-picoline, amrinone, benfurodil hemisucci-
nate, bucladesine, cerberosine, camphotamide, convali-
atoxin, cymarin, denopamine, deslanoside, digitalin,
digitalis, digitoxin, digoxin, dobutamine, dopamine, dopex-
amine, enoximone, erythrophleine, fenalcomine, gitalin,
gitoxin, glycocyamine, heptaminol, hydrastinine, ibopatnine,
a lanatoside, metamivam, milrinone, nerifolin, oleandrin,
ouabain, oxyfedrine, prenalterol, proscillaridine, resibufoge-
nin, scillaren, scillarenin, strphanthin, sulmazole, theobro-
mine and xarnoterol.
In particular embodiments, an intropic agent is a cardiac
glycoside, a beta-adrenergic agonist or a phosphodiesterase
inhibitor. Non-limiting examples of a cardiac glycoside
includes digoxin (lanoxin) and digitoxin (crystodigin). Non-
limiting examples ofa B-adrenergic agonistinclude albuterol,
bambuterol, bitolterol, carbuterol, clenbuterol, clorprenaline,
denopamine,dioxethedrine, dobutamine (dobutrex), dopam-
ine (intropin), dopexamine, ephedrine, etafedrine, ethylnore-
pinephrine, fenoterol, formoterol, hexoprenaline, ibopamine,
isoetharine, isoproterenol, mabuterol, metaproterenol, meth-
oxyphenamine, oxyfedrine, pirbuterol, procaterol, protoky-
lol, reproterol, rimiterol, ritodrine, soterenol, terbutaline, tre-
toquinol, tulobuterol and xamoterol. Non-limiting examples
of a phosphodiesterase inhibitor include amrinone(inocor).
Antianginal agents may comprise organonitrates, calcium
channel blockers, beta blockers and combinations thereof.
Non-limiting examples of organonitrates, also known as
nitrovasodilators, include nitroglycerin (nitro-bid,nitrostat),
isosorbide dinitrate (isordil, sorbitrate) and amy]nitrate (as-
pirol, vaporole).
Endothelin (ET) is a 21-aminoacid peptide that has potent
physiologic and pathophysiologic effects that appear to be
involved in the developmentofheart failure. The effects ofET
are mediated through interaction with two classes of cell
surface receptors. The type A receptor (ET-A)is associated
with vasoconstriction and cell growth while the type B recep-
tor (ET-B) is associated with endothelial-cell mediated
vasodilation and with the release of other neurohormones,
such as aldosterone. Pharmacologic agents that can inhibit
either the production of ET orits ability to stimulate relevant
cells are known in the art. Inhibiting the production of ET
involvesthe use ofagents that block an enzyme termed endot-
helin-converting enzymethat is involved in the processing of
the active peptide from its precursor. Inhibiting the ability of
ETto stimulate cells involves the use of agents that block the
interaction ofET withits receptors. Non-limiting examples of
endothelin receptor antagonists (ERA) include Bosentan,
Enrasentan, Ambrisentan, Darusentan, Tezosentan, Atrasen-
tan, Avosentan, Clazosentan, Edonentan, sitaxsentan, TBC
3711, BQ 123, and BQ 788.
In certain embodiments, the secondary therapeutic agent
may comprise a surgery of some type, which includes, for
example, preventative, diagnostic or staging, curative and
palliative surgery. Surgery, and in particular a curative sur-
gery, may be used in conjunction with other therapies, such as
the present invention and one or more other agents.
Such surgical therapeutic agents for vascular and cardio-
vascular diseases and disorders are well known to those of
skill in the art, and may comprise, but are not limited to,
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performing surgery on an organism, providing a cardiovas-
cular mechanical prostheses, angioplasty, coronary artery
reperfusion, catheter ablation, providing an implantable car-
dioverter defibrillator to the subject, mechanical circulatory
support or a combination thereof. Non-limiting examples ofa
mechanical circulatory support that may be used in the
present invention comprise an intra-aortic balloon counter-
pulsation, left ventricular assist device or combination
thereof.
In another embodiment, the present invention provides a
methodoftreating or preventing a musculoskeletal disorder
in a subject in need thereof comprising (a) identifying a
subject havingorat risk ofa musculoskeletal disorder; and (b)
increasing the expression and/oractivity ofone or more miR-
15 family members in skeletal muscle cells of said subject.
The disorder may be selected from the group consisting of
muscular dystrophy, disuse atrophy, muscle wasting in
response to anti-gravity and denervation. Increasing the
expression and/or activity may comprise administering said
one or more miR-15 family membersto said subject, option-
ally comprised within a lipid vehicle, or may comprise
administering an expression vector that expresses said one or
more miR-15 family members in said subject. The expression
vector may be aviral expression vector, such as an adenoviral
expression vector, or a non-viral expression vector, such as
one comprised within a lipid vehicle. The method mayfurther
comprise a non-miR-15 family membertherapy (i.e. another
microRNAor other appropriate therapy).
The present invention also encompasses a pharmaceutical
composition comprising an inhibitor of one or more miR-15
family members (e.g. miR-195, miR-497, miR-424, miR-
15a, miR-15b, miR-16-1, and miR-16-2). The pharmaceuti-
cal composition may comprise any inhibitor of a miR-15
family memberas described herein, such as an antagomir, an
antisense oligonucleotide, an inhibitory RNA molecule, anda
nucleic acid comprising one or more miR-15 bindingsites.
Whereclinical applications are contemplated, pharmaceuti-
cal compositions will be prepared in a form appropriate for
the intended application. Generally, this will entail preparing
compositions that are essentially free of pyrogens, as well as
other impurities that could be harmful to humansor animals.
Colloidal dispersion systems, such as macromolecule
complexes, nanocapsules, microspheres, beads, and lipid
based systems including oil-in-water emulsions, micelles,
mixed micelles, and liposomes, may be used as delivery
vehicles for the oligonucleotide inhibitors of microRNA
function or constructs expressing inhibitory nucleotides.
Commercially available fat emulsions that are suitable for
delivering the nucleic acids ofthe inventionto tissues, such as
cardiac muscle tissue, include Intralipid®, Liposyn®, Lipo-
syn® II, Liposyn® III, Nutrilipid, and other similar lipid
emulsions. A preferred colloidal system for use as a delivery
vehicle in vivo is a liposome(i.e., an artificial membrane
vesicle). The preparation and use of such systems is well
knownin the art. Exemplary formulations are also disclosed
in USS. Pat. No. 5,981,505; U.S. Pat. No. 6,217,900; U.S. Pat.
No. 6,383,512; U.S. Pat. No. 5,783,565; U.S. Pat. No. 7,202,
227; U.S. Pat. No. 6,379,965; U.S. Pat. No. 6,127,170; U.S.
Pat. No. 5,837,533; U.S. Pat. No. 6,747,014; and WO03/
093449, which are herein incorporated by reference in their
entireties.
One will generally desire to employ appropriate salts and
buffers to render delivery vehicles stable and allow for uptake
by target cells. Buffers also will be employed when recom-
binant cells are introduced into a patient. Aqueous composi-
tions ofthe present invention comprise an effective amount of
the delivery vehicle or cells, dissolved or dispersed in a phar-
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maceutically acceptable carrier or aqueous medium. The
phrases “pharmaceutically acceptable” or “pharmacologi-
cally acceptable”refer to molecular entities and compositions
that do not produceadverse, allergic, or other untoward reac-
tions when administered to an animal or a human. As used
herein, “pharmaceutically acceptable carrier” includes sol-
vents, buffers, solutions, dispersion media, coatings, antibac-
terial and antifungal agents, isotonic and absorption delaying
agents andthe like acceptable for use in formulating pharma-
ceuticals, such as pharmaceuticals suitable for administration
to humans. The use of such media and agents for pharmaceu-
tically active substances is well known in the art. Except
insofar as any conventional media or agent is incompatible
with the active ingredients of the present invention,its use in
therapeutic compositions is contemplated. Supplementary
active ingredients also can be incorporated into the composi-
tions, provided they do not inactivate the vectors or cells of
the compositions.
The active compositions of the present invention may
include classic pharmaceutical preparations. Administration
ofthese compositions accordingto the present invention may
be via any common route so long as the target tissue is
available via that route. This includes oral, nasal, or buccal.
Alternatively, administration may be by intradermal, subcu-
taneous, intramuscular, intraperitoneal or intravenousinjec-
tion, or by direct injection into cardiac tissue. Pharmaceutical
compositions comprising miRNA inhibitors or expression
constructs encoding inhibitory polynucleotides may also be
administeredby catheter systemsor systemsthat isolate coro-
nary circulation for delivering therapeutic agentsto the heart.
Various catheter systems for delivering therapeutic agents to
the heart and coronary vasculature are known in the art. Some
non-limiting examples of catheter-based delivery methods or
coronary isolation methods suitable for use in the present
invention are disclosed in U.S. Pat. No. 6,416,510; U.S. Pat.
No. 6,716,196; U.S. Pat. No. 6,953,466, WO 2005/082440,
WO 2006/089340, U.S. Patent Publication No. 2007/
0203445, U.S. Patent Publication No. 2006/0148742, and
U.S. Patent Publication No. 2007/0060907, which are all
herein incorporated by reference in their entireties. Such
compositions wouldnormally be administered as pharmaceu-
tically acceptable compositions, as described supra.
The active compounds mayalso be administered parenter-
ally or intraperitoneally. By way ofillustration, solutions of
the active compounds as free base or pharmacologically
acceptable salts can be prepared in water suitably mixed with
a surfactant, such as hydroxypropylcellulose. Dispersions
can also be preparedin glycerol, liquid polyethylene glycols,
and mixtures thereofandin oils. Under ordinary conditions of
storage and use, these preparations generally contain a pre-
servative to prevent the growth of microorganisms.
The pharmaceutical forms suitable for injectable use or
catheter delivery include, for example, sterile aqueous solu-
tionsor dispersions andsterile powders for the extemporane-
ous preparation ofsterile injectable solutions or dispersions.
Generally, these preparationsare sterile and fluid to the extent
that easy injectability exists. Preparations should be stable
under the conditions of manufacture and storage and should
be preserved against the contaminating action ofmicroorgan-
isms, such as bacteria and fungi. Appropriate solvents or
dispersion media may contain, for example, water, ethanol,
polyol (for example, glycerol, propylene glycol, and liquid
polyethylene glycol, and the like), suitable mixtures thereof
and vegetable oils. The properfluidity can be maintained, for
example, by the use of a coating, such as lecithin, by the
maintenance of the required particle size in the case of dis-
persion and by the use of surfactants. The prevention of the
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action of microorganisms can be brought about by various
antibacterial and antifungal agents, for example, parabens,
chlorobutanol, phenol, sorbic acid, thimerosal, and the like.
In manycases,it will be preferable to include isotonic agents,
for example, sugars or sodium chloride. Prolonged absorp-
tion of the injectable compositions can be brought about by
the use in the compositions ofagents delaying absorption, for
example, aluminum monostearate and gelatin.
Sterile injectable solutions maybe prepared by incorporat-
ing the active compounds in an appropriate amount into a
solvent along with any other ingredients (for example as
enumerated above) as desired, followedbyfiltered steriliza-
tion. Generally, dispersions are prepared by incorporating the
various sterilized active ingredients into a sterile vehicle
which contains the basic dispersion medium andthe desired
other ingredients, e.g., as enumerated above. In the case of
sterile powders for the preparation ofsterile injectable solu-
tions, the preferred methods of preparation include vacuum-
drying and freeze-drying techniques which yield a powder of
the active ingredient(s) plus any additional desired ingredient
from a previously sterile-filtered solution thereof.
The compositions of the present invention generally may
be formulated in a neutral or salt form. Pharmaceutically-
acceptable salts include, for example, acid addition salts
(formed with the free amino groupsofthe protein) derived
from inorganic acids (e.g., hydrochloric or phosphoric acids,
or from organic acids (e.g., acetic, oxalic, tartaric, mandelic,
and thelike. Salts formed with the free carboxyl groups ofthe
protein can also be derived from inorganic bases (e.g.,
sodium, potassium, ammonium,calcium, or ferric hydrox-
ides) or from organic bases(e.g., isopropylamine, trimethy-
lamine,histidine, procaine andthe like.
Upon formulation, solutionsare preferably administered in
a manner compatible with the dosage formulation and in such
amountas is therapeutically effective. The formulations may
easily be administered in a variety of dosage forms such as
injectable solutions, drug release capsules and the like. For
parenteral administration in an aqueous solution, for
example, the solution generally is suitably buffered and the
liquid diluentfirst rendered isotonic for example with suffi-
cient saline or glucose. Such aqueoussolutions may be used,
for example, for intravenous, intramuscular, subcutaneous
and intraperitoneal administration. Preferably, sterile aque-
ous media are employedas is knownto those ofskill in theart,
particularly in light of the present disclosure. By way of
illustration, a single dose may be dissolved in 1 ml of isotonic
NaC]solution and either added to 1000 ml ofhypodermocly-
sis fluid or injected at the proposedsite of infusion, (see for
example, “Remington’s Pharmaceutical Sciences” 15th Edi-
tion, pages 1035-1038 and 1570-1580). Some variation in
dosage will necessarily occur depending on the condition of
the subject being treated. The person responsible for admin-
istration will, in any event, determine the appropriate dosefir
the individual subject. Moreover, for human administration,
preparations should meetsterility, pyrogenicity, general
safety and purity standards as required by FDA Office of
Biologics standards.
Any of the compositions described herein may be com-
prised in a kit. In a non-limiting example, an inhibitor of one
or more miR-15 family members, such as an antagomur, is
included in a kit. The kit may contain two or more, three or
more, four or more, five or more, or six inhibitors for each
miR-15 family member. By way of example, the kit may
contain an inhibitor ofmiR-195 andan inhibitor ofmiR-15a.
All possible combinations of inhibitors for miR-15 family
members are contemplated by the invention. The kit may
further include water and/or buffers to stabilize the inhibitory
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polynucleotides. The kit may also include one or more trans-
fection reagent(s) to facilitate delivery of the miRNA inhibi-
tors to cells.
The components of the kits may be packaged either in
aqueous media or in lyophilized form. The container means
of the kits will generally include at least one vial, test tube,
flask, bottle, syringe or other container means, into which a
component maybeplaced, and preferably, suitably aliquoted.
Wherethere is more than one componentin the kit (labeling
reagent and label may be packagedtogether), the kit also will
generally contain a second, third or other additional container
into which the additional components may be separately
placed. However, various combinations of components may
be comprisedin a vial. The kits of the present invention also
will typically include a means for containing the nucleic
acids, and any other reagent containers in close confinement
for commercial sale. Such containers may include injection or
blow-moldedplastic containers into which the desired vials
are retained.
Whenthe componentsofthe kit are provided in one and/or
moreliquid solutions, the liquid solution is an aqueous solu-
tion, with a sterile aqueous solution being particularly pre-
ferred.
However, the components of the kit may be provided as
dried powder(s). When reagents and/or componentsare pro-
vided as a dry powder, the powder can be reconstituted by the
addition ofa suitable solvent. It is envisioned that the solvent
mayalso be provided in another container means.
The container means will generally include at least one
vial, test tube, flask, bottle, syringe and/or other container
means, into which the nucleic acid formulations are placed,
preferably, suitably allocated. The kits may also comprise a
second container meansfor containing a sterile, pharmaceu-
tically acceptable buffer and/or other diluent.
Such kits may also include components that preserve or
maintain the miRNA inhibitors or that protect against their
degradation. Such components may be RNAse-freeorprotect
against RNAses. Such kits generally will comprise, in suit-
able means,distinct containers for each individual reagent or
solution.
A kit will also include instructions for employing the kit
components as well the use ofany other reagent not included
in the kit. Instructions may include variations that can be
implemented. A kit may also include utensils or devices for
administering the miRNA inhibitor by various administration
routes, such as parenteral or catheter administration.
Tt is contemplated that such reagents are embodiments of
kits ofthe invention. Such kits, however, are not limited to the
particular items identified above and may include any reagent
used for the manipulation or characterization of miRNA.
The present invention further comprises methodsfor iden-
tifying modulators of miR-15 family members. Identified
inhibitors of the function of one or more miR-15 family
membersare useful in the prevention or treatmentor reversal
of cardiac hypertrophy or heart failure. Modulators (e.g.
inhibitors) of miR-15 family members may be included in
pharmaceutical compositions tier the treatment of cardiac
disorders according to the methodsofthe present invention.
These assays may comprise random screening of large
libraries of candidate compounds; alternatively, the assays
may be used to focus on particular classes of compounds
selected with an eye towards structural attributes that are
believed to make them more likely to inhibit the expression
and/or function of miR-15 family members.
To identify a modulator of a miR-15 family member, one
generally will determine the function of a miR-15 family
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memberin the presence and absence of the candidate com-
pound. For example, a method generally comprises:
(a) providing a candidate compound;
(b) admixing the candidate compound with a miR-15 fam-
ily member;
(c) measuring activity of the miR-15 family member; and
(d) comparingthe activity in step (c) with the activity in the
absenceofthe candidate compound,
wherein a difference between the measuredactivities indi-
cates that the candidate compound is a modulator of a
miR-1.5 family member.
Assays also may be conductedin isolated cells, organs, or in
living organisms.
Assessing the activity or expression of a miR-15 family
member may comprise assessing the expression level of the
miR-15 family member. Thosein theart will be familiar with
a variety of methods for assessing RNA expression levels
including, for example, northern blotting or RT-PCR.Assess-
ing the activity or expression of the miR-15 family member
may comprise assessing the activity of the miR-15 family
member. In some embodiments, assessing the activity of the
ma-15 family member comprises assessing expression or
activity of a gene regulated by the miR-15 family member.
Genes regulated by miR-15 family members include, for
example, FGF2, TGFb-induced factor 2, BCL9I, BCL2L,
CDC25A,cyclin E1, cyclin D1, and cyclin D2. Thosein the
art will be familiar with a variety ofmethodsfor assessing the
activity or expression of genes regulated by miR-15 family
members. Such methodsinclude, for example, northern blot-
ting, RT-PCR, ELISA, or western blotting.
It will, of course, be understood that all the screening
methods of the present invention are useful in themselves
notwithstanding the fact that effective candidates may not be
found. The invention provides methodsfor screening for such
candidates, not solely methodsoffinding them.
As used herein the term “candidate substance”refers to any
molecule that may potentially modulate the function ofmiR-
15 family members. Onewill typically acquire, from various
commercial sources, molecular libraries that are believed to
meetthe basic criteria for useful drugs in an effort to “brute
force” the identification of useful compounds. Screening of
such libraries, including combinatorially-generated libraries
(e.g., antagomir libraries), is a rapid and efficient way to
screen large numberofrelated (and unrelated) compoundsfor
activity. Combinatorial approaches also lend themselves to
rapid evolution of potential drugs by the creation of second,
third, and fourth generation compounds modeled on active,
but otherwise undesirable compounds. Non-limiting
examples of candidate compounds that may be screened
according to the methods of the present invention are pro-
teins, peptides, polypeptides, polynucleotides, oligonucle-
otides or small molecules, Modulators of miR-15 family
members may also be agonistsor inhibitors ofupstream regu-
lators of any one of the miR-15 family members.
A quick, inexpensive and easy assay to run is an in vitro
assay. Such assays generally use isolated molecules, can be
run quickly and in large numbers, thereby increasing the
amountofinformation obtainable in a short period of time k
variety ofvessels may be usedto run the assays, including test
tubes, plates, dishes and other surfaces such as dipsticks or
beads.
A technique for high throughput screening of compounds
is described inWO 84/03564, whichis herein incorporated by
reference in its entirety. Large numbers of small antagomir
compounds may be synthesized on a solid substrate, such as
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plastic pins or some other surface. Such molecules can be
rapidly screening for their ability to hybridize to miR-15
family members.
The present invention also contemplates the screening of
compounds for their ability to modulate expression and/or
function of one or more miR-15 family membersin cells.
Various cell lines, including those derived from skeletal
muscle cells, can be utilized for such screening assays,
including cells specifically engineered for this purpose. Pri-
mary cardiac cells also may be used, as can the H9C2cellline.
In vivo assays involve the use of various animal models of
heart disease, including transgenic animals, that have been
engineeredto have specific defects, or carry markers that can
be used to measure the ability of a candidate compound to
reach and affect different cells within the organism. Due to
their size, ease of handling, and information on their physi-
ology and genetic make-up, mice are a preferred embodi-
ment, especially for transgenics. However, other animals are
suitable as well, includingrats, rabbits, hamsters, guinea pigs,
gerbils, woodchucks, cats, dogs, sheep, goats, pigs, cows,
horses and monkeys (including chimps, gibbons and
baboons). Assays for inhibitors may be conducted using an
animal model derived from any of these species.
Treatmentofanimals with test compoundswill involve the
administration of the compound, in an appropriate form, to
the animal. Administration will be by any route that could be
utilized for clinical purposes. Determining the effectiveness
of a compound in vivo may involve a variety of different
criteria, including but notlimited to alteration ofhypertrophic
signaling pathways and physical symptoms of hypertrophy.
Also, measuring toxicity and dose response can be performed
in animals in a more meaningful fashion than in in vitro or in
cyto assays.
In one embodiment, the present invention provides a
method ofregulating cardiac cell survival comprising admin-
istering to cardiac cells a modulator of one or more miR-15
family members. In another embodiment, the modulator is an
agonist ofthe expressionor activity ofa miR-15 family mem-
ber. In another embodiment, cardiaccell survival is decreased
following administration of an agonist of a miR-15 family
member. In another embodiment, the modulator of a miR-15
family memberis an inhibitor of the expression or activity of
a miR-15 family member.In still another embodiment, car-
diac cell survival is increased following administration of an
inhibitor of a miR-15 family member.
In a further embodiment, the present invention provides a
method of regulating apoptosis of cardiac cells comprising
administering to cardiac cells a modulator of one or more
miR-15 family members. In another embodiment, the modu-
lator is an agonist of the expression or activity of a miR-15
family member. In another embodiment, apoptosis ofcardiac
cells is increased following administration of an agonist of a
miR-15 family member. In another embodiment, the modu-
lator ofamiR-15 family memberis an inhibitor ofthe expres-
sion or activity of a miR-15 family member.In still another
embodiment, apoptosis of cardiac cells is decreased follow-
ing administration of an inhibitor of a miR-15 family mem-
ber. In some embodiments, the expression of FGF2, TGFb-
induced factor 2, BCL9I, BCL2L, CDC25A, cyclin E1,
cyclin D1, or cyclin D2 is increased ina cell by contacting the
cell with a miR-15 family inhibitor. In other embodiments,
expression ofFGF2, TGFb-inducedfactor 2, BCL9I, BCL2L,
CDC25A,cyclin E1, cyclin D1, or cyclin D2 is decreased in
a cell by contacting the cell with a miR-15 family agonist.
Thus, the present invention includes a method ofregulating
expression ofFGF2, TGFb-inducedfactor 2, BCL9I, BCL2L,
CDC25A,cyclin El, cyclin D1, or cyclin D2 in a cell com-
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prising contacting the cell with a modulator of a miR-15
family member. In one embodiment, the expression ofFGF2,
TGFb-induced factor 2, BCL9I, BCL2L, CDC25A,cyclin
E1, cyclin D1, or cyclin D2 is decreased in the cell following
administration of a miR-15 family agonist. In another
embodiment, the expression of FGF2, TGFb-induced factor
2, BCL9I, BCL2L, CDC25A,cyclin E1, cyclin D1, or cyclin
D2 is increased in the cell following administration of a
miR-15 family inhibitor.
An agonist of a miR-15 family member maybea poly-
nucleotide comprising a mature sequenceor a star sequence
from a miR-15 family member. In one embodiment,the poly-
nucleotide comprises the sequence ofSEQ ID NO: 7, SEQ ID
NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ
ID NO:12, SEQ ID NO:13, SEQID NO: 14, SEQID NO:15,
SEQ ID NO:16, SEQ ID NO: 17, SEQ ID NO:20, or SEQ ID
NO: 21. In another embodiment, the agonist of a miR-15
family member may be a polynucleotide comprising thepri-
miRNAor pre-miRNA sequence for a miR-15 family mem-
ber(e.g. pre-miR-195, pre-miR-497, pre-miR-424, pre-miR-
15a, pre-miR-15b, pre-miR-16-1, or pre-miR-16-2). For
example, in one embodiment, the agonist may be a polynucle-
otide comprising a sequence of SEQ ID NO:1, SEQ ID NO:
2, SEQID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO:
6, or SEQ ID NO:19. The polynucleotide comprising the a
mature sequence of miR-15 family member may be single
stranded or double stranded. The polynucleotides may con-
tain one or more chemical modifications, such as locked
nucleic acids, peptide nucleic acids, sugar modifications,
such as 2'-O-alkyl (e.g. 2'-O-methyl, 2'-O-methoxyethyl),
2'-fluoro, and 4' thio modifications, and backbone modifica-
tions, such as one or more phosphorothioate, morpholino, or
phosphonocarboxylate linkages. In one embodiment, the
polynucleotide comprising a miR-15 family member
sequence is conjugated to cholesterol. In another embodi-
ment, the agonist ofamiR-15 family membermay be an agent
distinct from the miR-15 family memberthat acts to increase,
supplement, or replace the function of the miR-15 family
member. In another embodiment, the miR-15 family agonist
may be expressed in vivo from a vector.
In one embodiment, the present invention provides a
method for treating pathologic cardiac hypertrophy, heart
failure, or myocardial infarction in a subject in need thereof
comprising: identifying a subject having cardiac hypertrophy,
heart failure, or myocardial infarction; and administering an
inhibitor of one or more miR-15 family membersto the sub-
ject. In certain embodiments of the invention the miR-15
family inhibitor may be identified by a method comprising:
(a) contacting a cell with a candidate compound;(b) assessing
activity or expression of a miR-15 family member; and (c)
comparing the activity or expression in step (b) with the
activity or expression in the absence of the candidate com-
pound, wherein a reduction in the activity or expression ofthe
miR-15 family memberin the cell contacted with the candi-
date compound comparedto the activity or expression in the
cell in the absence of the candidate compound indicates that
the candidate compoundis an inhibitor ofthe miR-15 family
member.
A particular embodimentofthe present invention provides
transgenic animals that lack one or both functionalalleles of
a miR-15 family member. Also, transgenic animals that
express miR-15 family members under the control of an
inducible, tissue selective or a constitutive promoter, recom-
binant cell lines derived from such animals, and transgenic
embryos may be useful in determining the exactrote that the
miR-15 family memberplays the development and differen-
tiation of cardiomyocytes and in the development of patho-
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logic cardiac hypertrophy and heart failure. Furthermore,
these transgenic animals may provide an insight into heart
development. The use of constitutively expressed miR-15
family members provides a model for over or unregulated
expression. Also, transgenic animals that are “knocked out”
for one or more miR-15 family members, in one or both
alleles, are contemplated.
In a general embodiment, a transgenic animal is produced
by the integration of a given transgene into the genome in a
mannerthat permits the expression ofthe transgene. Methods
for producing transgenic animals are generally described by
Wagner and Hoppe (U.S. Pat. No. 4,873,191; incorporated
herein by reference), and Brinsteret al. (1985; incorporated
herein by reference).
Typically, a gene flanked by genomic sequencesis trans-
ferred by microinjection into a fertilized egg. The microin-
jected eggs are implantedinto a host female, and the progeny
are screened for the expression of the transgene. Transgenic
animals may be produced from the fertilized eggs from a
number of animals including, but not limited to reptiles,
amphibians, birds, mammals, andfish.
DNA clones for microinjection can be prepared by any
meansknowninthe art. For example, DNA clones for micro-
injection can be cleaved with enzymesappropriate for remov-
ing the bacterial plasmid sequences, and the DNA fragments
electrophoresed on 1% agarose gels in TBE buffer, using
standard techniques. The DNA bandsare visualized by stain-
ing with ethidium bromide, and the band containing the
expression sequences is excised. The excised band is then
placed in dialysis bags containing 0.3 M sodium acetate, pH
7.0. DNA is electroeluted into the dialysis bags, extracted
with a 1:1 phenol:chloroform solution and precipitated by
two volumesof ethanol. The DNAis redissolved in 1 ml of
low salt buffer (0.2 M NaCl, 20 mM Tris, pH 7.4, and 1 mM
EDTA)andpurified on an Elutip-D™column. The column is
first primed with 3 ml ofhigh salt buffer (1 M NaCl, 20 mM
Tris, pH 7.4, and 1 mM EDTA) followed by washing with 5
mlof low salt buffer. The DNA solutions are passed through
the column three times to bind DNAto the column matrix.
After one wash with 3 mloflow salt buffer, the DNA is eluted
with 0.4 ml high salt buffer and precipitated by two volumes
of ethanol. DNA concentrations are measured by absorption
at 260 nm in a UV spectrophotometer. For microinjection,
DNA concentrations are adjusted to 3 ug/ml in 5 mM Tris, pH
7.4 and 0.1 mM EDTA. Other methods for purification of
DNA for microinjection are described in Palmiter et al.
(1982); and in Sambrooket al. (2001).
In an exemplary microinjection procedure, female mice six
weeksofage are inducedto superovulate with a 5 IU injection
(0.1 cc, ip) of pregnant mare serum gonadotropin (PMSG;
Sigma) followed 48 hourslater by a 5 IU injection (0.1 cc, ip)
ofhuman chorionic gonadotropin (hCG; Sigma). Females are
placed with males immediately after hCG injection. Twenty-
one hours after hCG injection, the mated females are sacri-
ficed by C02 asphyxiation or cervical dislocation and
embryos are recovered from excised oviducts and placed in
Dulbecco’s phosphate buffered saline with 0.5% bovine
serum albumin (BSA; Sigma). Surrounding cumuluscells are
removed with hyaluronidase (1 mg/ml). Pronuclear embryos
are then washed and placed in Earle’s balancedsalt solution
containing 0.5% BSA (EBSS) in a 37.5° C. incubator with a
humidified atmosphere at 5% CO,, 95% air until the time of
injection. Embryos can be implanted at the two-cell stage.
Randomly cycling adult female miceare paired with vasec-
tomized males. C57BL/6 or Swiss mice or other comparable
strains can be used for this purpose. Recipient females are
mated at the same time as donor females. At the time of
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embryotransfer, the recipient females are anesthetized with
an intraperitoneal injection of 0.015 ml of 2.5% avertin per
gram of body weight. The oviducts are exposed bya single
midline dorsal incision. An incision is then made through the
body wall directly over the oviduct. The ovarian bursa is then
torn with watchmakers forceps. Embryosto be transferred are
placed in DPBS (Dulbecco’s phosphate buffered saline) and
in the tip of a transfer pipet (about 10 to 12 embryos). The
pipet tip is inserted into the infundibulum and the embryos
transferred. After the transfer, the incision is closed by two
sutures.
As used herein, the term “heart failure” is broadly used to
mean any condition that reduces the ability of the heart to
pumpblood. Asa result, congestion and edema develop in the
tissues. Most frequently, heart failure is caused by decreased
contractility ofthe myocardium,resulting from reduced coro-
nary blood flow; however, many other factors may result in
heart failure, including damage to the heart valves, vitamin
deficiency, and primary cardiac muscle disease. Though the
precise physiological mechanisms of heart failure are not
entirely understood, heart failure is generally believed to
involve disorders in several cardiac autonomic properties,
including sympathetic, parasympathetic, and baroreceptor
responses. The phrase “manifestations of heart failure” is
used broadly to encompassall ofthe sequelae associated with
heart failure, such as shortness of breath, pitting edema, an
enlarged tender liver, engorged neck veins, pulmonary rales
and the like including laboratory findings associated with
heart failure.
The term “treatment” or grammatical equivalents encom-
passes the improvementand/or reversal of the symptoms of
heart failure (i.e., the ability of the heart to pump blood).
“Improvementin the physiologic function” of the heart may
be assessed using any of the measurements described herein
(e.g., measurementofejectionfraction, fractional shortening,
left ventricular internal dimension, heart rate, etc.), as well as
any effect upon the animal’s survival. In use of animal mod-
els, the response of treated transgenic animals and untreated
transgenic animals is compared using any of the assays
described herein (in addition, treated and untreated non-
transgenic animals may be included as controls). A com-
pound which causes an improvement in any parameter asso-
ciated with heart failure used in the screening methodsofthe
instant invention may thereby be identified as a therapeutic
compound.
The term “dilated cardiomyopathy”refers to a type ofheart
failure characterized by the presence of a symmetrically
dilated left ventricle with poor systolic contractile function
and, in addition, frequently involves the right ventricle.
The term “compound”refers to any chemical entity, phar-
maceutical, drug, and the like that can be used to treat or
prevent a disease, illness, sickness, or disorder of bodily
function. Compounds comprise both known and potential
therapeutic compounds.A compound canbe determinedto be
therapeutic by screening using the screening methods of the
present invention.A “known therapeutic compound”refersto
a therapeutic compoundthat has been shown(e.g., through
animal trials or prior experience with administration to
humans)to be effective in such treatment. In other words, a
known therapeutic compoundis not limited to a compound
efficacious in the treatmentofheart failure.
As used herein, the term “cardiac hypertrophy”refers to
the process in which adult cardiac myocytes respondto stress
through hypertrophic growth. Such growth is characterized
by cell size increases without cell division, assembling of
additional sarcomeres within the cell to maximize force gen-
eration, and an activation of a fetal cardiac gene program.
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Cardiac hypertrophyis often associated with increased risk of
morbidity and mortality, and thus studies aimed at under-
standing the molecular mechanismsof cardiac hypertrophy
could have a significant impact on humanhealth.
As used herein, the term “modulate”refers to a change or
an alteration in a biological activity. Modulation may be an
increase or a decrease in protein activity, a change in kinase
activity, a change in binding characteristics, or any other
changein the biological, functional, or immunological prop-
erties associated with the activity of a protein or other struc-
ture of interest. The term “modulator” refers to any molecule
or compound which is capable of changing oraltering bio-
logical activity as described above.
The term “B-adrenergic receptor antagonist” refers to a
chemical compound or entity that is capable of blocking,
either partially or completely, the beta (B) type of adrenore-
ceptors (1.e., receptors of the adrenergic system that respond
to catecholamines, especially norepinephrine). Some (-adr-
energic receptor antagonists exhibit a degree of specificity for
one receptor subtype (generally B,); such antagonists are
termed “B,-specific adrenergic receptor antagonists” and
“B.,-specific adrenergic receptor antagonists.” The term
B-adrenergic receptor antagonist” refers to chemical com-
pounds that are selective and non-selective antagonists.
Examples of f-adrenergic receptor antagonists include, but
are not limited to, acebutolol, atenolol, butoxamine,carteolol,
esmolol, labetolol, metoprolol, nadolol, penbutolol, pro-
panolol, and timolol. The use of derivatives of known (-adr-
energic receptor antagonists is encompassed by the methods
ofthe present invention. Indeed any compound, which func-
tionally behaves as a B-adrenergic receptor antagonist is
encompassed by the methods ofthe present invention.
The terms “angiotensin-converting enzyme inhibitor” or
“ACEinhibitor”refer to a chemical compoundorentity that
is capable of inhibiting, either partially or completely, the
enzyme involved in the conversion ofthe relatively inactive
angiotensin I to the active angiotensinI] in the rennin-angio-
tensin system. In addition, the ACE inhibitors concomitantly
inhibit the degradation of bradykinin, which likely signifi-
cantly enhances the antihypertensive effect oftheACE inhibi-
tors. Examples ofACE inhibitors include, but are not limited
to benazepril, captopril, enalapril, fosinopril, quiapril and
ramipril. The use of derivatives of known ACEinhibitors is
encompassed by the methodsofthe present invention. Indeed
any compound,whichfunctionally behaves as anACEinhibi-
tor, is encompassed by the methodsofthe present invention.
As used herein, the term “genotypes”refers to the actual
genetic make-up ofan organism, while “phenotype”refers to
physical traits displayed by an individual. In addition, the
“phenotype” is the result of selective expression of the
genome(1.e., it is an expression of the cell history and its
response to the extracellular environment). Indeed, the
human genomecontains an estimated 30,000-35,000 genes.
In each cell type, only a small (1.e., 10-15%)fraction ofthese
genes are expressed.
The use of the word “a”or “an” when used in conjunction
with the term “comprising” in the claims and/or the specifi-
cation may mean “one,” but it is also consistent with the
meaning of “one or more,” “at least one,” and “one or more
than one.”
It is contemplated that any embodiment discussed herein
can be implemented with respect to any method or composi-
tion of the invention, and vice versa. Furthermore, composi-
tions andkits ofthe invention can be used to achieve methods
of the invention.
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Throughout this application, the term “about” is used to
indicate that a value includes the standard deviation of error
for the device or method being employed to determine the
value.
The use of the term “or” in the claims is used to mean
“and/or” unless explicitly indicated to refer to alternatives
only or the alternatives are mutually exclusive, although the
disclosure supportsa definition that refers to only alternatives
and “and/or,”
Asused in this specification and claim(s), the words “com-
prising” (and any form ofcomprising, suchas “comprise” and
“comprises”), “having” (and any form of having, such as
“have” and “has”’), “including” (and any form of including,
such as “includes” and “include”) or “containing” (and any
form of containing, such as “contains” and “contain’’) are
inclusive or open-ended and do not exclude additional, unre-
cited elements or methodsteps.
The following examples are included to further illustrate
various aspects of the invention. It should be appreciated by
those of skill in the art that the techniques disclosed in the
examples which follow represent techniques and/or compo-
sitions discovered by the inventors to function well in the
practice of the invention, and thus can be considered to con-
stitute preferred modes for its practice. However, those of
skill in the art should, in light of the present disclosure,
appreciate that many changes can be made in the specific
embodiments which are disclosed andstill obtain a like or
similar result without departing from the spirit and scope of
the invention.
EXAMPLES
Example 1
Regulation of Cardiac Hypertrophy and Heart
Failure by Stress-Responsive miRNAs
In light oftheir involvement in modulating cellular pheno-
types, the inventors have hypothesized that miRNAs may
play a role in regulating the response of the heart to cardiac
stress, which is knownto result in transcriptional and trans-
lational changes in gene expression. To investigate the poten-
tial involvement of miRNAs in cardiac hypertrophy, a side-
by-side miRNA microarray analysis was performed in two
established mouse models of cardiac hypertrophy, using a
microarray that represented 186 different miRNAs. Mice that
were subjected to thoracic aortic banding (TAB), which
induces hypertrophy by increasedafterload on the heart (Hill
et al., 2000), were compared to sham operated animals. In a
second model, transgenic mice expressing activated cal-
cineurin (CnA) in the heart, which results in a severe, well-
characterized form of hypertrophy (Molkentin et al., 1998),
were compared to wild-type littermates (FIG. 1A). RNA iso-
lated from hearts ofmice subjected to TAB showedincreased
expression of 27 miRNAs compared to sham-operated con-
trols, and CnA. Tg mice showed increased expression of 33
miRNAs compared with non-transgenic littermate controls,
of which 21 were up-regulated in both models. Similarly,
TAB and CnA-induced hypertrophy were accompanied by
reduced expression of 15 and 14 miRNAs,respectively, of
which 7 miRNAs were down-regulated in common (FIG.
1B). Northern analysis of expression of these miRNAs and
previous microarray analyses (Baradet al., 2004; Sempere et
al., 2004; Shingaraet al., 2005; Babaket al., 2004; Liu etal.,
2004) indicate that they are expressed in a wide range of
tissues.
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Based ontheir relative expression levels, conservation of
human, rat and mouse sequences, and levels of expression
during hypertrophy, the inventors focused on 11 up- and 5
down-regulated miRNAs. Northern blot analysis ofRNA iso-
lated from cardiac tissue from WT and CnA Tg animals
confirmed an increased expression ofmiR-21, miR-23, miR-
24, miR-125b, miR-195, miR-199a, and miR-214, and
decreased expression of miR-29c, miR-93, miR-150 and
miR-181b (FIG. 1C). Collectively, these data indicate that
distinct miRNAsare regulated during cardiac hypertrophy,
suggesting the possibility that they might function as modu-
lators of this process.
Ventricular hypertrophy developsin response to numerous
forms of cardiac stress and often leads to heart failure in
humans (Arad et al., 2002). Northern blot analysis of the
hypertrophy-regulated miRNAsin idiopathic end-stagefail-
ing human hearts showed increased expression of miR-24,
miR-125b, miR-195, miR-199a and miR-214, while the
expression for miR-23 appeared to be variable within the
non-failing and failing groups (FIG. 2). No changein expres-
sion of miR-21, miR-27, miR-29c, miR-93, miR-150 and
miR-181b was found (data not shown). Thus, the altered
pattern ofmiRNAexpression in the failing human heart over-
lapped with that of the hypertrophic mouseheart, suggesting
that these miRNAsrepresent a molecular signature ofadverse
cardiac remodeling.
Example 2
Cardiac Over-Expression ofmiR-195 is Sufficient to
Drive Cardiac Hypertrophy
MiR-24, miR-195 and miR-214 were overexpressed spe-
cifically in the heart under the control of the a-myosin heavy
chain (MHC)promoter, F1 offspring could not be obtained
for miR-24, suggesting that cardiac over-expression of this
miRNA causes embryoniclethality. Since all offspring ofthe
miR-195 transgenic (Tg) line 3 died in the first two weeks
after birth due to heart failure (FIG. 3), the Tg line 1 for
miR-195, which was viable, was used for further studies.
Northern blot analysis showed miR-195 to be expressed at
levels ~25-fold above normal in Tg line 1 (FIG. 3). Over-
expression ofmiR-195 initially induced cardiac growth with
disorganization of cardiomyocytes, which progressed to a
dilated phenotype by 6 weeks of age. Although there were
some fibrotic lesions, the dramatic increase in size of indi-
vidual myocytes in miR-195 Tg mice comparedto wild-type
(WT) was morestriking (FIG.3).
Echocardiography on 6 week-old animals showed that
miR-195 Tg mice displayed thinning ofthe left ventricular
walls (AWs and PWs),an increase in left ventricular diameter
(LVIDd and LVIDs) anda deterioration in cardiac function, as
indicatedby decreased fractional shortening (FIG. 4A). Heart
weightto body weight ratios were also dramatically increased
in miR-195 Tg animals compared to WTlittermates, indicat-
ing that overexpression of miR-195 was sufficient to stimu-
late cardiac growth (FIG. 4B). Real-time PCR analysis on
cardiac tissue from miR-195 Tg animals comparedto their
WTlittermates, revealed dramatic up-regulation ofthe hyper-
trophic markersatrial natriuretic factor (ANF), b-type natri-
uretic protein (BNP) and B-myosin heavy chain (BMHC) in
response to cardiac over-expression of miR-195 (FIG. 4C).
In contrast to the dramatic effects of overexpression of
miR-195 on cardiac structure, function, and gene expression,
cardiac over-expression of miR-214 at levels comparable to
those ofmiR-195 had no phenotypic effect (FIGS. 4C and 5,
and data not shown). Thus, the cardiac remodeling induced in
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the miR-195 Tg animals is specifically due to functional
effects ofthis miRNA rather than a general non-specific effect
resulting from miRNA over-expression. These results indi-
cate that increased expression of miR-195 induces hyper-
trophic signaling leading to cardiac failure. Since miR-195
belongs to a small family of related miRNAs, the miR-15
family, other family membersare also likely to participate in
cardiac disease.
The ability of miR-195 to promote cardiac growth con-
trasts with that of miR-1, a muscle-specific miRNA that
inhibits cardiac growth by suppressing the expression of the
bHLHprotein Hand2 (Zhaoet al., 2005). miR-1 is highly
expressed in the adult heart, but miR-195 is apparently
capable of over-riding the inhibitory influence of miR-I on
cardiac growth.
It is especially interesting that overexpression in cardi-
omyocytes of the miRNAsthat were down-regulated during
hypertrophy caused an apparent reduction in cell size, an
effect opposite than that evoked by the upregulated miRNAs.
Oneinterpretation of these results is that these miRNAsnor-
mally function to suppress growth and are therefore down-
regulated to enhance hypertrophy.
miRNA-195 belongs to a small family ofmicroRNAs,the
miR-15 family, which contains miR-195, miR-16-1, miR-
15a, miR-15b, miR-16-2, miR-424, and miR-497. Four ofthe
miR-15 family members are expressed as three clustered
transcripts (FIG. 6A). Using a variety of bioinformatics
approaches, potential mRNAtargets for raiR-195 were iden-
tified. Several ofthe identified target mRNAs encodeproteins
involved in cell proliferation, survival and anti-apoptosis
(FIG. 6B). Oneofthe predicted targets for the miR-15 family
is FGF2, which has been shown to promote cardiac repair
(FIG.7). All members of the miR-15 family are up-regulated
in failing human hearts, indicating that this family ofmicroR-
NAsplays a key role in pathological cardiac remodeling
(FIG.8). Since all the miR-15 family members share a con-
served seed sequence, all miR-15 family members could be
inhibited simultaneously by targeting the seed sequence. One
such approach entails overexpression of a nucleic acid con-
taining multiple binding sites, which comprise a sequence
complementary to the seed sequence. The nucleic acid would
“scavenge” or “sponge” all separate members because of
their overlap in seed region and consequently overlap in target
sequence (FIG. 8B) (Ebert et al., 2007).
All publications, patents, and patent applications discussed
and cited herein are incorporated herein by reference in their
entireties. All ofthe compositions and methods disclosed and
claimed herein can be made and executed without undue
experimentation in light of the present disclosure. While the
compositions and methods of this invention have been
described in termsofpreferred embodiments,it will be appar-
ent to those of skill in the art that variations may be applied to
the compositions and methods, and in the steps or in the
sequence of steps of the methods described herein without
departing from the concept, spirit and scope ofthe invention.
Morespecifically, it will be apparentthat certain agents which
are both chemically and physiologically related may be sub-
stituted for the agents described herein while the same or
similar results would be achieved.All such similar substitutes
and modifications apparent to those skilled in the art are
deemed to be within the spirit, scope and concept of the
invention as defined by the appended claims.
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SEQUENCE LISTING
<160> NUMBER OF SEQ ID NOS: 21
<210>
<211>
<212>
<213>
SEQ ID NO 1
LENGTH: 87
TYPE: RNA
ORGANISM: Homo sapiens
<400> SEQUENCE: 1
agcuucccug gcucuagcag cacagaaaua uuggcacagg gaagegaguc ugecaauauu
ggcugugeug cuccaggcag gguggug
<210>
<211>
<212>
<213>
SEQ ID NO 2
LENGTH: 112
TYPE: RNA
ORGANISM: Homo sapiens
<400> SEQUENCE: 2
ccaceceggu ccugcucceg ceccagcage acacuguggu uuguacggca cuguggecac
guccaaacca cacuguggug uuagagegag ggugggggag geaccgecga gg
<210> SEQ ID NO 3
60
87
60
112
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<211> LENGTH: 89
<212> TYPE: RNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 3
gucageagug ccuuagcage acguaaauau uggcguuaag auucuaaaau uaucuccagu
auuaacugug cugcugaagu aagguugac
<210> SEQ ID NO 4
<211> LENGTH: 81
<212> TYPE: RNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 4
guuccacucu agcagcacgu aaauauugge guagugaaau auauauuaaa caccaauauu
acugugcuge uuuaguguga ¢c
<210>
<211>
<212>
<213>
<400>
SEQ ID NO 5
LENGTH: 83
TYPE: RNA
ORGANISM: Homo sapiens
SEQUENCE: 5
ccuuggagua aaguagcage acauaauggu uuguggauuu ugaaaaggug caggcecauau
ugugcugecu caaaaauaca agg
<210>
<211>
<212>
<213>
<400>
SEQ ID NO 6
LENGTH: 98
TYPE: RNA
ORGANISM: Homo sapiens
SEQUENCE: 6
uugaggcecuu aaaguacugu agcagcacau caugguuuac augcuacagu caagaugcega
aucauuauuu gcugcucuag aaauuuaagg aaauucau
<210> SEQ ID NO 7
<211> LENGTH: 21
<212> TYPE: RNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 7
uageagcaca gaaauauugg c
<210> SEQ ID NO 8
<211> LENGTH: 22
<212> TYPE: RNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 8
ccaauauugg cugugcugcu cc
<210> SEQ ID NO 9
<211> LENGTH: 21
<212> TYPE: RNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 9
cagcagcaca cugugguuug u
<210> SEQ ID NO 10
<211> LENGTH: 22
60
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<212> TYPE: RNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 10
caaaccacac ugugguguua ga
<210> SEQ ID NO 11
<211> LENGTH: 22
<212> TYPE: RNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 11
uageagcacg uaaauauugg cg
<210> SEQ ID NO 12
<211> LENGTH: 22
<212> TYPE: RNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 12
ccaguauuaa cugugcugcu ga
<210> SEQ ID NO 13
<211> LENGTH: 22
<212> TYPE: RNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 13
ccaauauuac ugugcugeuu ua
<210> SEQ ID NO 14
<211> LENGTH: 22
<212> TYPE: RNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 14
uageagcaca uaaugguuug ug
<210> SEQ ID NO 15
<211> LENGTH: 22
<212> TYPE: RNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 15
caggccauau ugugcugecu ca
<210> SEQ ID NO 16
<211> LENGTH: 22
<212> TYPE: RNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 16
uageagcaca ucaugguuua ca
<210> SEQ ID NO 17
<211> LENGTH: 22
<212> TYPE: RNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 17
egaaucauua uuugcugcuc ua
<210> SEQ ID NO 18
22
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<211> LENGTH: 8
<212> TYPE: RNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 18
agcagcac
<210> SEQ ID NO 19
<211> LENGTH: 98
<212> TYPE: RNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 19
cgaggggaua cagcagcaau ucauguuuug aaguguucua aaugguucaa aacgugagge
gceugcuauac ccccucgugg ggaagguaga aggugggg
<210> SEQ ID NO 20
<211> LENGTH: 22
<212> TYPE: RNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 20
cagcagcaau ucauguuuug aa
<210>
<211>
<212>
<213>
SEQ ID NO 21
LENGTH: 21
TYPE: RNA
ORGANISM: Homo sapiens
<400> SEQUENCE: 21
caaaacguga ggcgcugcua u
60
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Whatis claimed is:
1. A methodof treating pathologic cardiac hypertrophy,
heart failure, or myocardial infarction in a subject in need
thereofcomprising administering to said subject an antisense
oligonucleotide comprising a sequence that is at least par-
tially complementary to a miR-15b sequence, wherein one or
more symptomsofpathologic cardiac hypertrophy, heart fail-
ure, or myocardial infarction is improved in the subject fol-
lowing administration of the antisense oligonucleotide.
2. The method of claim 1, wherein the antisense oligo-
nucleotide comprises a sequence that is at least partially
complementary to the sequence of SEQ ID NO:16.
3. The method of claim 2, wherein the antisense oligo-
nucleotide comprises a sequencethat is fully complementary
to the sequence of SEQ ID NO: 16.
4. The method of claim 1, wherein the antisense oligo-
nucleotide comprises a sequence that is at least partially
complementary to the sequence of SEQ ID NO:6.
5. The method of claim 2, wherein the antisense oligo-
nucleotide comprises a sequencethat is fully complementary
to the sequence of SEQ ID NO:6.
6. The method of claim 1, wherein said antisense oligo-
nucleotide is about 19 to about 25 nucleotides in length.
7. The method of claim 1, wherein said antisense oligo-
nucleotide is about 15 nucleotides in length.
8. The method of claim 1, wherein the antisense oligo-
nucleotide has at least one chemical modification.
9. The method of claim 8, wherein said chemical modifi-
cation is a sugar modification or a backbone modification.
10. The method ofclaim 9, wherein the sugar modification
is a 2'-O-alkyl, 2'-O-methyl, 2'-O-methoxyethyl, 2'-fluoro, or
4'thio modification.
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11. The method of claim 9, wherein the backbone modifi-
cation is a phosphorothioate linkage.
12. The method ofclaim 8, wherein said chemical modifi-
cation is a locked nucleicacid.
13. The method of claim 1, wherein said improved symp-
toms include increased exercise capacity, increased cardiac
ejection volume, decreasedleft ventricular end diastolic pres-
sure, decreased pulmonary capillary wedge pressure,
increased cardiac output, increased cardiac index, lowered
pulmonary artery pressures, decreased left ventricular end
systolic and diastolic dimensions, decreased left and right
ventricular wall stress, decreased wall tension, and reduction
in infarct size.
14. The method of claim 1, wherein the antisense oligo-
nucleotide is administered by parenteral, oral, subcutaneous,
intravenous, intramuscular, intradermal, intraperitoneal,
transdermal, sustained release, controlled release, delayed
release, suppository, catheter, or sublingual administration or
direct injection into cardiac tissue.
15. The method ofclaim 1, further comprising administer-
ing to the subject a second therapy.
16. The method ofclaim 15, wherein said second therapyis
selected from the group consisting of a beta blocker, an iono-
trope, a diuretic, ACE-I, All antagonist, BNP, a Ca**-blocker,
an endothelin receptor antagonist, and an HDAC inhibitor.
17. The method of claim 1, wherein the antisense oligo-
nucleotide is expressed from a vector under the control of a
promoter.
18. The method of claim 17, wherein the promoter is a
cardiac-specific promoter.
* * * * *
